CA2108575C - Method of manufacturing solid dispersion - Google Patents
Method of manufacturing solid dispersion Download PDFInfo
- Publication number
- CA2108575C CA2108575C CA002108575A CA2108575A CA2108575C CA 2108575 C CA2108575 C CA 2108575C CA 002108575 A CA002108575 A CA 002108575A CA 2108575 A CA2108575 A CA 2108575A CA 2108575 C CA2108575 C CA 2108575C
- Authority
- CA
- Canada
- Prior art keywords
- polymer
- agents
- solid dispersion
- drug
- hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Abstract
The object of this invention is to provide a process for producing a solid dispersion, which has overcome the disadvantages of the conventional production technology for solid dispersions, The invention comprises employing a twin-screw extruder in the production of a solid dispersion. In accordance with the invention, a solid dispersion can be expediently produced without heating a drug and a polymer to or beyond their melting points and without using an organic solvent for dissolving both components and the resulting solid dispersion has excellent performance characteristics.
Description
SPECIFICATION
METHOD OF MANUFACTURING OF SOLID DISPERSION
TECHNICAL FIELD
The present invention relates to a process for producing a solid dispersion, More particularly, the invention relates to a process for producing a solid dispersion utilizing a twin-screw extruder, which finds application chiefly in the field of pharmaceutical manufacture.
The term 'solid dispersion' is used herein to mean a drug-containing pharmaceutical bulk substance comprising the drug dissolved or dispersed in a polymer.
BACKGROUND ART
Solid dispersions are of use for an enhanced solubility of drugs or for controlling the rate of release of a drug from a dosage form or improving the bioavailability of drugs, thus being of significant commercial value.
The conventional technology for the production of a solid dispersion includes a fusion process which is characterized by melting a drug and a polymer together at elevated temperature and, then, cooling the melt to solidify, a solvent process which is characterized by dissolving a drug and a polymer in an appropriate solvent and, then, removing the solvent, and a fusion-solvent process which has the characteristics of said processes, However, the fusion process has the disadvantage that it cannot be applied to a drug or polymer which is, or is likely to be, thermally degraded, The solvent process is free from the above-mentioned disadvantage of the fusion process but because it employs an organic solvent such as an alcohol or a chlorine-containing solvent, this process has the following disadvantages, (1) When an alcohol is used as the solvent, strict measures must be provided for the prevention of an explosion hazard during production, 2~~$~'~5 (2) Since organic solvents have fairly high affinities for the polymer, they cannot be easily removed from the product solid dispersions, (3) Removal of the solvent necessarily results in its diffusion into the atmosphere to cause an atmospheric pollution, (4) After removal of the solvent, the solid dispersion adhering intimately to the vessel wall cannot be easily withdrawn from the vessel, DISCLOSURE OF INVENTION
The object of the present invention is to establish an improved process for producing a solid dispersion which has overcome the above-mentioned inherent disadvantages of the fusion and solvent processes, The substantive feature of the present invention resides in the processing of the drug, polymer and other components for a solid dispersion by utilizing a twin-screw extruder, The present invention is now described in detail, The twin-screw extruder is a forward-discharge extruder-granulator characterized by the use of a couple of screws, which differentiate the machine from the so-called single-screw extruder, To be more specific, the twin-screw extruder comprises a metering feeder unit, a barrel (cylinder), screws, paddle means, screw shafts, barrel heater-cooler means, exit dies (cooling die, heating die, molding die) and extrudate cutter and provides for a free variation of compounding pressure and molding temperature through a choice of screw geometry, rotational speed, and screw elements to be mounted on the screw shafts, Furthermore, if necessary, the barrel can be used in a variety of combinations of length and type according to the intended use and its temperature can also be controlled as desired, Thus, the twin-screw extruder processes the feed with two screws and provides for change of the combination of axial screw elements so that it has many definite advantages over the single-screw extruder, viz, (1) In the twin-screw extruder, the respective screws influence each other so that the material is not rotated together with the screws and, hence, the compounding is not much influenced by characteristics of the material, Therefore, the twin-screw extruder is capable of processing an oil-rich or water-rich material which cannot be successfully processed by the single-screw extruder.
(2) Compared with the single-screw extruder, the twin-screw extruder is by far superior in shear force, compounding effect and transport capacity, Therefore, in the processing of a protein, for instance, the structurization of the protein which cannot be achieved with the single-screw extruder can be accomplished with the twin-screw extruder, (3) The twin-screw extruder features a minimum heat of friction of the barrel and is, therefore, conducive to the ease of temperature control, As a consequence, the twin-screw extruder is more suited for pharmaceuticals which are vulnerable to high temperature, The polymer to be used in the present invention can be virtually any natural or synthetic polymer that can be generally used as a raw material in the manufacture of pharmaceutical products and such that its functions are not adversely affected by the passage through the small die orifice or orifices of the twin-screw extruder, Among such polymer are pH-dependent polymers, pH-independent polymers and water-soluble polymers, for instance, and specifically include the following, Hydroxypropylmethylcellulose phthalate 220824 (HP50)~
hydroxypropylmethylcellulose phthalate 220'731 (HP55), hydroxypropylmethylcellulose acetate succinate (A90AT), carboxymethylethylcellulose (CMEC), cellulose acetate phthalate (CAP), methacrylic copolymer LD (L30D55), methacrylic copolymer S
(S-100), aminoalkyl methacrylate copolymer E (gastric coating base), polyvinyl acetal) diethylaminoacetate (AEA), polyvinylpyrrolidone (K-25, 30, 90~ PVP), ethylcellulose (EC), methacrylic copolymer RS (RS 30D), polyvinyl alcohol (PVA), methylcellulose (MC), hydroxypropylcellulose (HPC), hydroxypropylmethylcellulose 2208 (Metolose 90SH), hydroxypropylmethylcellulose 2906 (Metolose 65SH), hydroxypropylmethylcellulose 2910 (Metolose 60SH), carboxymethylcellulose sodium (sodium cellulose glycolate), dextrin, pullulan, Acacia, tragacanth, sodium alginate, propylene glycol alginate, agar powder, gelatin, starch, processed starch, phospholipids (lecithin), glucomannan and so on, The polymers can be used independently or, if necessary, in a combination of two or more species, The particle diameter of said polymer need not necessarily be finer that the size which can be fed from the hopper to the body of the twin-screw extruder and is generally not greater than 7000 a m and preferably not greater than 2000 ,u m, Coarser polymers can also be used by comminuting them beforehand, The processing parameters such as pressure, temperature, feed rate of material, amounts and feed rates of water, plasticier and other additives in the production process of the present invention are dependent on the type of drug and of polymer, the twin-extruder model used and other conditions but it is important to select a combination of parameters such that the drug, polymer, etc. will be maintained at temperatures below their decomposition points and vary the operating parameters according to the desired characteristics of the product, The compounding ratio of the drug to the polymer should vary with the species of drug and of polymer, the objective, film characteristics and so on, Based on each part of the drug, the proportion of the polymer is generally 0.1 to 999 parts, preferably 0.5 to 500 Parts and for still better results, 1 to 50 parts, When the system contains a thermally labile drug and/or polymer, an aqueous solution or dispersion of a plasticizer may be added to the material prior to feeding to the twin-screw extruder or during compounding. Since this practice lowers the transition temperature of the polymer, the molding temperature setting can then be lower than the decomposition points of the drug and polymer to prevent thermal degradation of the drug and polymer. Of course, an aqueous plasticizer solution or dispersion may be added in the same manner when no heat-labile drug or polymer is contained in the system, As the plasticizer which can be used for depressing the transition temperature of the polymer, those compounds which are generally used as plasticizers for film coating compositions in the pharmaceutical field can be mentioned, For example, the following compounds can be mentioned, Cetanol, medium chain triglycerides, polyoxyethylene-polyoxypropylene glycol (Pluronic), macrogols (200, 300 400 1000. 1500. 1540. 4000, 6000, 20000) triacetin, triethyl citrate (Citroflex), etc, It should be understood that the plasticizes which can be used in the present invention is not limited to the species mentioned above but can be any compound having the property to lower the transition temperature of the polymer, The level of addition of said plasticizes is dependent on the types of drug and polymer used but is appropriately 1 to 80~ and preferably 5 to 5096 relative to the polymer, The method for addition of the plasticizes may be direct addition to the system containing the polymer and the drug before compounding or addition of an aqueous solution or dispersion of the plasticizes in the course of molding, There is no particular limitation on the method~of addition, The drug which can be used in the present invention is not particularly limited but is preferably a non-heat-labile drug, particularly a drug which is not decomposed at any temperature not exceeding 50°C. As such drugs, there can be mentioned the following, among others, 1. Antipyretic, analgesic and antiinflammatory agents Indomethacin, aspirin, diclofenac sodium, ketoprofen, ibuprofen, mefenamic acid, dexamethasone, dexamethasone sodium sulfate, hydrocortisone, prednisolone, azulene, phenacetin, isopropylantipyrine, acetaminophen, benzydamine hydrochloride, phenylbutazone, flufenamic acid, sodium salicylate, choline salicylate, Sasapyrine (salsalate), clofezone, etodolac, 2. Antiulcer agents Sulp hide, cetraxate hydrochloride, gefarnate, i irsogladine maleate, cimetidine, ranitidine hydrochloride, famotidine, nizatidine, roxatidine acetate hydrochloride.
3. Coronary vasodilators Nifedipine, isosorbide dinitrate, diltiazem hydrochloride, trapidil, dipyridamole, dilazep dihydrochloride, methyl 2,6-dimethyl-4-(2-nitrophenyl)-5-(2-oxo-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydropyridine-3-carboxylate, verapamil, nicardipine, nicardipine hydrochloride, verapamil hydrochloride, 4. Peripheral vasodilators Ifenprodil tartrate, cinepazide maleate, cyclandelate, cinnarizine, pentoxiphylline.
5. Antibiotics Ampicillin, amoxicillin, cefalexin, erythromycin ethyl succinate, bacampicillin hydrochloride, minocycline hydrochloride, chloramphenicol, tetracycline, erythromycin, 6. Synthetic antimicrobial agents Nalidixic acid, piromidic acid, pipemidic acid trihydrate, enoxacin, cinoxacin, ofloxacin, norfloxacin, ciprofloxacin hydrochloride, sulfamethoxazole-trimethoprim, 6-fluoro-1-methyl-7-[4-(5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl-1-piperazinyl]-4-oxo-4H[1,3]-thiazeto[3,2-a]quinoline-3-carboxylic acid, _7_ Antispasmodic agents Propantheiine bromide, ,.:ropine sulfate, ~xapmm bromide, timepidium bromide, scopolamine butylbromide, trospium chloride, butropium bromide, ~f-methylscopolamine methyisulfate, octatropine methylbromide.
Antitussm a and antiasthmatic agents iheophylline, aminophyiline, methylephedrine hydrochloride, procaterol hydrochloride, trimethoquinol hydrochloride, codeine phosphate, cromoglicate sodium, tranilast, dextromethorphan hydrobromide, dimemorfan phosphate, clobutinol hydrochloride, tominoben hydrochloride, benproperine phosphate, tipepidine hibenzate, eprazinone hydrochloride, clofedanol hydrochloride, ephedrine hydrochloride, noscapine, carbetapentane citrate, oxeladin tannate, isoaminile citrate, 9. Bronchodilators Diprophylline, salbutamol sulfate, clorprenaline hydrochloride, formoterol fumarate, orciprenaline sulfate, pirbuterol hydrochloride, hexoprenaline-sulfate, bitolterol mesilate, clenbuterol hydrochlo'~ide, terbutaline sulfate, mabuterol hydrochloride, fenoterol hydrobromide,.methoxyphenamine hydrochloride.
Diuretics Furosemide, acetazoiamide, trichlormethiazide, cyclothiazide, hydrochlorothiazide, hydroflumethiazide, ethiazide, cyclopentiazide, spironolactone, triamterene, chlorothiazide, ;i~ -g,-piretanide, mefruside, atacrynic ~ciG, azosemide, cicienamide, 11. Muscle relaxants Chlorophenesin carbamate, toiperisone hydrochloride, eperisone hydrochloride, tizanidine hydrochloride, mephenesin, chlorzoxazone, phenprodamate, methocarbamoi, chlormeza~none, pridinoi mesiiate, aiioqualone, ;;aclofen, cant;ciene sodium 12. Cerebral metabolism Improving agents ~leciofenoxate hydrochloride.
13. Minor tranquilizers Oxazolam, diazepam, clotiazepam, medazepam, temazepam, fludiazepam, meprobamate, nitrazepam, chlordiazepoxide.
19. 'Major tranquilizers Su~piride, clocapramine hydrochloride, zotepine, chloropromazine, haloperidol.
15. ,~ -Elockers Pindolol, propranolol hydrochloride, carteolol hydrochloride, metoprolol tartrate, labetalol hydrochloride, oxprenolol hydrochloride, acebutolol hydrochloride, bufetolol hydrochloride, alprenolol hydrochloride, arotinolol hydrochloride, nadolol, bucumolol hydrochloride, indenolol hydrochloride, timolol maleate, befunolol hydrochloride.
A
16. ,4ntiarrhythmic agents Procainamide hydrochloride, disopyramide, a~maline, quinidine sulfate, aprindine hydrochloride, propafenone hydrochloride, mexiletine hydrochloride, Antigout agents ~llopurinol, probeneci;:, ..cichicme, suifinpyrazone, benzbromarone, bucolome, 18. Anticoagulants Ticlopidine hydrochloride, dicoumarol, warfarin potassium.
Antiepiieptics Phenytoin, sodium vaiproate, metharbital, carbamazepine.
20. Antihistaminics Chlorpheniramine maleate, clemastine fumarate, mequitazine, alimemazine tartrate, cyproheptadine hydrochloride, 21. Antiemetics Difenidol hydrochloride, metoclopramide, domperidone, betahistine m~s::~;:, trimebutine maleate, 22. Antihypertensive agents Dimethylaminoethyl reserpilinate hydrochloride, rescinnamine, methyldopa, prazosin hydrochloride, bunazosin hydrochloride, clonidine hydrochloride, budralazine, urapidil, 23. Sympathomimetic agents Dihydroergotamine mesilate, isoproterenol hydrochloride, etilefrine hydrochloride.
2a_, expectorants Bromhexine hydrocnioriae, carbocystem e, system a ethyl ester hydrochloride, system a methyl ester hydrochloride, 25. Ural antidiabetic agents Glibenclamide, tolbutamide, glymidine sodium, 26. ~.ardicvascular system drugs l:bidecarenone, ATP 2;Va.
2~_ Iron preparations Ferrous sulfate, dried iron sulfate.
2g. Vitamins Vitamin B,, vitamin B2, vitamin Be, vitamin 8,~, vitamin C, folic acid, 29. Therapeutic agents for pollakiuria Flavoxate hydrochloride, oxybutynin hydrochloride, terodiline hydrochloride, ~-diethylamino-1,1-dimethyl-2-butynyl (+)-a -cyclohexyl-a -phenylglycolate hydrochloride monohydrate.
30. ~'n8iotensin converting enzyme inhibitors Enalapril maleate, alacepril, delapril hydrochloride, The solid dispersion prepared according to the invention can be easily comminuted using an appropriate mill or the like to provide a finely divided solid dispersion, which can be directly utilized as powders or granules, It can also be processed into a variety of dosage forms for oral administration, such as tablets, granules, fine granules, capsules, semi-solid dispersion-filled capsules, oily substance-filled capsules and so on, -1 l In October 1991, a technology for the manufacture of a controlled release dosage form utilizing a single-screw extruder was disclosed (CapsuleNews, June/July, Vol. 1, No. 3. Warner-Lambert Co,), However, the technology disclosed in the above literature is a process using a single-screw extruder which is by far interior to the twin-screw extruder as pointed out hereinbefore and the product is also distinct from the solid dispersion provided by the process of the present invention, Furthermore, the above technology is intended for the manufacture of a slow release dosage form and this slow release dosage farm is manufactured at high temperature, Therefore, the above technology is irrelevant to the process of the invention which is intended for the manufacture of a solid dispersion overcoming the disadvantages of the prior art fusion and solvent processes, EFFECTS OF INVENTION
In accordance with the present invention, a solid dispersion can be provided without exposing the drug and polymer to high temperature and without use of any organic solvent, In accordance with the invention, a solid dispersion can be molded and taken out in a pure form and a solid dispersion of any desired size and shape can be manufactured by varying the discharge die orifice diameter and configuration, Furthermore, other disadvantages of the fusion and solvent processes are successfully obviated, BEST MODE OF PRACTICING THE INVENTION
The following examples, comparative Examples and Test Examples are intended to describe the present invention in further detail, Example 1 Five-hundred (500) grams of Compound A (compound name: methyl 2, 6-dimethyl-4-(2-nitrophenyl)-5-(2-oxo-1, 3, 2-dioxaphosphorinan-2-yl)-1,4-dihydropyridine-3-carboxylate; the same applies hereinafter) was pulverized and this bulk powder (mean particle diameter: 60 ~ m) was blended with 2500 g of hydr-oxypropylmethylcellulose acetate succinate (tradename: A90AT, AS-MF, Shin-etsu Chemical; the same applies hereinafter), Then, while a small quantity of water was added, the mixture was processed using a twin-screw extruder (KEX-30, Kurimoto Iron Works; the same applies hereinafter) equipped with a 4 mm ~ x 2-orifice die at a barrel temperature of 100 °C and an extrusion speed of 200 rpm to provide an extrudate (solid dispersion), This extrudate was pulverized in a sample mill (Model AP-S, Hosokawa Iron Works; the same applies hereinafter) and the finely-divided powder thus obtained was used as samples for the release test (65-100 mesh), power K-ray diffraction analysis (250 mesh pass) and solubility (65-100 mesh).
Example 2 Five-hundred (500) grams of indomethacin was blended with 2500 g of hydroxypropylmethylcellulose phthalate (tradename:
HPMCP, HP-55F grade, Shin-etsu Chemical; the same applies hereinafter), and while a 5096 (w/w) aqueous solution of triethyl citrate was added, the composition was molded using a twin-screw extruder equipped with a 4 mm ~ x 2-orifice die at a barrel temperature of $0°C and an extrusion speed of 200 rpm to provide an extrudate (solid dispersion), This extrudate was comminuted in a sample mill and the resulting finely divided powder was used as samples for the release test, powder X-ray diffraction analysis and solubility, Example 3 Five-hundred (500) grams of indomethacin was blended with 1500 g of polyvinyl acetal) diethylaminoacetate (trademark: AEA, Sankyo Organic Chemicals) and while a 5096 (w/w) aqueous solution of triacetin was added, the composition was molded using a twin-screw extruder equipped with a 4 mm ~ x 2-orifice die at a barrel temperature of 90°C and an extrusion speed of 200 rpm to provide an extrudate (solid dispersion), Example 4 Two-hundred (200) grams of Compound B (compound name: 4-diethylamino-l,l-dimethyl-2-butynyl (+)- a -cyclohexyl-a -phenyl-glycolate hydrochloride monohydrate) was blended with 1600 g of methacrylic copolymer LD (tradename: Eudragit, grade L30D55, available from K.K. Higuchi Shokai) and 200 g of wheat starch, Then, while water was added (poured), the composition was molded using a twin-screw extruder equipped with a ø mm~ x 2-orifice die at a barrel temperature of 100 °C and an extrusion speed of 200 rpm to provide an extrudate (solid dispersion), Example 5 Two-thousand (2000) grams of a 1:1 (w/w) mixture of indomethacin and ethyl cellulose (tradename: Ethocel, STD-45 type, Dow Chemical,) was weighed out and wheat starch was added at the three levels of 300 g, 500 g and 1000 g. While a 596 (w/w) aqueous solution of triacetin was added at the rate of 5 ml/min,, each of the above mixtures was molded using a twin-screw extruder equipped with 4 mm ~ x 2-orifice die at a barrel temperature of 80°C and an extrusion speed of 200 rpm to provide an extrudate (solid dispersion), Each of these extrudates was pulverized in a sample mill and the resulting finely divided powder (65-100 mesh) was used as test samples.
Example 6 Three-hundred (300) grams of nifedipine was blended with 1500 g of hydroxypropylmethylcellulose acetate succinate and while water was added, the composition was molded using a twin-screw extruder equipped with 4 mm ~ x 2-orifice die at a barrel temperature of 100 °C and an extrusion speed of 200 rpm to provide an extrudate (solid dispersion).
This extrudate was pulverized in a sample mill and the resulting finely divided powder was used as samples for the release test (65-100 mesh), power x-ray diffraction analysis (250 mesh pass) and solubility (65-100 mesh).
Example 7 Two-hundred (200) grams of oxybutynin hydrochloride was blended with 1000 g of hydroxypropylmethylcellulose acetate succinate and while water was added, the composition was molded using a twin-screw extruder equipped with 2 mm ~ x 3-orifice die at a barrel temperature of 100 °C and an extrusion speed of 200 rpm to provide an extrudate (solid dispersion).
This extrudate was pulverized in a sample mill and the resulting finely divided powder was used as samples for the release test (65-100 mesh), power X-ray diffraction analysis (250 mesh pass) and solubility (65-100 mesh).
Example 8 Two-hundred (200) grams of nicardipine hydrochloride was blended with 1000 B of hydroxypropylmethylcellulose phthalate and while a 50~ (w/w) aqueous solution of propylene glycol was added, the composition was molded using a twin-screw extruder equipped with 2 mm ~ x 3-orifice die at a barrel temperature of 80°C and an extrusion speed of 200 rpm to provide an extrudate (solid dispersion), This extrudate was pulverized in a sample mill and the resulting finely divided powder was used as samples for the release test (65-100 mesh), power X-ray diffraction analysis (250 mesh pass) and solubility (65-100 mesh).
Example 9 Five-hundred (500) 8rams of diclofenac sodium was blended with 2500 B of hydroxypropylmethylcellulose phthalate and while a 5096 (w/w) aqueous solution of triethyl citrate was added, the composition was molded using a twin-screw extruder equipped with 4 mm~ x 2-orifice die at a barrel temperature of 80°C and an extrusion speed of 150 rpm to provide an extrudate (solid dispersion), This extrudate was pulverized in a sample mill and the resulting finely divided powder was used as samples for the release test (65-100 mesh), power X-ray diffraction analysis (250 mesh pass) and solubility (65-100 mesh).
Comparative Example 1 Solvent Process Five (5) grams of Compound A and 25 g of hydr-oxypropylmethylcellulose acetate succinate were weighed out and dissolved by addition of 700 ml of ethanol and 300 ml of methylene chloride, Then, using a rotary evaporator, the solvent was thoroughly evaporated at 5p °C to provide a solid (solid dispersion), This solid was pulverized in a table-top compact mill and the resulting fine powder was size-selected to provide comparative test samples for the release test (65-100 mesh), powder K-ray diffraction analysis (250 mesh pass) and solubility test (65-100 mesh).
Comparative Example 2 Nc W SflEt T
Five (5) grams of nifedipine and 25 g of hydr-oxypropylmethylcellulose acetate succinate were weighed out and dissolved by addition of 700 ml of ethanol and 300 ml of methylene chloride, Then, using a rotary evaporator, the solvent was thoroughly evaporated at 50 °C to provide a solid (solid dispersion). This solid was pulverized in a table-top compact mill and the resulting fine powder was size-selected to provide comparative test samples for the release test (65-100 mesh), powder X-ray diffraction analysis (250 mesh pass) and solubility test (65-100 mesh).
Comparative Example 3 Five (5) grams of oxybutynin hydrochloride and 25 g of hydroxypropylmethylcellulose acetate succinate were weighed out and dissolved by addition of 700 ml of ethanol and 300 ml of methylene chloride. Then, using a rotary evaporator, the solvent was thoroughly evaporated at 50°C to provide a solid (solid dispersion). This solid was pulverized in a table-top compact mill and the resulting fine powder was size-selected to provide comparative test samples for the release test (65-100 mesh), powder K-ray diffraction analysis (250 mesh pass) and solubility test (65-100 mesh).
Comparative Example 4 Five (5) grams of nicardipine hydrochloride and 25 g of hydroxypropylmethylcellulose phthalate were weighed out and dissolved by addition of 700 ml of ethanol and 300 ml of methylene chloride. Then, using a rotary evaporator, the solvent was thoroughly evaporated at 50 °C to provide a solid (solid dispersion). This solid was pulverized in a table-top compact mill and the resulting fine powder was size-selected to provide comparative test samples for the release test (65-100 mesh), powder X-ray diffraction analysis (250 mesh pass) and solubility test (65-100 mesh), Comparative Example 5 Five (5) grams of diclofenac sodium and 25 g of hydroxypropylmethylcellulose phthalate were weighed out and dissolved by addition of 700 ml of ethanol and 300 ml of methylene chloride, Then, using a rotary evaporator, the solvent was thoroughly evaporated at 50 °C to provide a solid (solid dispersion). This solid was pulverized in a table-top compact mill and the resulting fine powder was size-selected to provide comparative test samples for the release test (65-100 mesh) and powder X-ray diffraction analysis (250 mesh pass), Test Example 1 The release test was carried out with the solid dispersions prepared in Example 1 (extruded product) and Comparative Example 1. As shown in Fig, 1, there was no release of Compound A under the conditions of JP Test Solution 1 (pH 1.2). 900 ml test solution and paddle speed 100 rpm. On the other hand, a quick release was obtained under the conditions of JP Test Solution 2 (pH 6.8), 900 ml test solution and paddle speed 100 rpm.
The above results indicated that the finely divided powder according to the process of the invention has the function of acting as an enteric coated product, Test Example 2 The solid products obtained in Example 1 and Comparative Example 1 were subjected to powder K-ray diffraction analysis, As shown in Fig, 2, the results showed the disappearance of peaks of Compound A crystals which had been observed with the bulk powder and a 1:1 physical mixture.
Test Example 3 The solubility of the test sample prepared in Example 1 was determined, As shown in Table 1, there was found an approximately 4-fold increase in solubility as compared with the bulk substance, This solubility value approximated that of the solid dispersion prepared by the solvent process in Comparative Example 1.
Table 1 Comparative Example 1 Example 1 Compounding ratio (Compound A:A90AT) 1:5 1:5 Solubility of Compound A in solid dispersion (,u g/ml)(1) 155 146 Solubility of Compound A
bulk substance ( ,u g/ml) (2) 36. 5 36. 5 Solubility ratio [(1)/(2)7 4.2 4.0 Test method: Saturation dissolution method Test conditions: Constant-temperature bath (25°C) Monocin (24-hr shaking, 24 cycles/min. ) JP Test Solution 2 Ultracentrifugation: 40000 rpm x 1 hr; the supernatant analyzed by HPLC, The results of Test Examples 1, 2 and 3 indicate that the extrudate retains the fundamental properties of an enteric coated product and, yet, has been converted to a solid dispersion, Test Example 4 The release test was carried out with the sample prepared in Example 2. As shown in Fig. 3, there was no release of indomethacin in JP Test Solution 1 (PH 1.2). On the other hand, a quick release was obtained in JP Test Solution 2 (pH 6.8).
The above results indicated that the finely divided powder according to the process of the invention has the function of acting as an enteric coated product, Test Example 5 The sample obtained in Example 2 was subjected to powder K-ray diffraction analysis, As shown in Fig, 4, the results showed the disappearance of peaks of indomethacin crystals which had been observed with the bulk powder and a l:l physical mixture, Test Example 6 The solubility of the solid dispersion prepared in Example 2 (extruded product) was determined, There was found an approximately 2-fold increase in solubility as compared with the bulk substance, This solubility value approximated that of the solid dispersion prepared by the solvent process, Test Example 7 The 35 mg indomethacin equivalent of the sample obtained in Example 5 was weighed and added to 900 ml of JP Test Solution 1 (pH 1.2) and the release test was carried out at a paddle speed of 100 rpm using a measuring wavelength of 320 nm, The result shown in Fig, 5 indicates that the release of indomethacin was suppressed and that the rate of release increased with an increasing amount of wheat starch added, Test Example 8 The release test was carried out with the solid dispersions prepared in Example 6 and Comparative Example 2, As shown in Fig, 6, there was no release of nifedipine in JP Test Solution 1 (pH 1.2). On the other hand, a quick release was obtained in JP
Test Solution 2 (PH 6.8).
The above results indicated that the finely divided powder according to the process of the invention has the function of acting as an enteric coated product, Test Example g The solid products obtained in Example 6 and Comparative Example 2 were subjected to powder H-ray diffraction analysis, As shown in Fig, 7, the results showed the disappearance of peaks of nifedipine crystals which had been observed with the bulk powder and a 1:1 physical mixture, Test Example 10 The solubility of the solid products prepared in Example 6 and Comparative Example 2 was determined, As shown in Table 2, there was found an approximately 5-fold increase in solubility as compared with the bulk substance. This solubility value was close to that of the solid dispersion prepared by the solvent process in Comparative Example 2.
Table 2 Comparative Example 6 Example 2 Compounding ratio (Nifedipine:A90AT) 1:5 1:5 Solubility of nifedipine in sol id dispersion ( ,u g/ml) (1) 26. 3 28. 6 Solubility of nifedipine bulk substance ( ,u g/ml) (2) 5. 6 5. 6 Solubility ratio [(1)/(2)~ 4.7 5.1 Test method: Saturation dissolution method Test conditions: Constant-temperature bath (25°C) Monocin (24-hr shaking, 24 cycles/min,) JP Test Solution 2 Ultracentrifugation: 40000 rpm x 1 hr; the supernatant analyzed by HPLC.
The results of Test Examples 8, 9 and 10 indicate that the extrudate containing nifedipine retains the fundamental properties of an enteric coated product and, yet, has been converted to a solid dispersion.
Test Example 11 The release test was carried out with the solid dispersions prepared in Example 7 and Comparative Example 3. As shown in Fig. 8, there was no release of oxybutynin hydrochloride in JP
Test Solution 1 (pH 1.2). On the other hand, a quick release was obtained in JP Test Solution 2 (PH 6.8).
The above results indicated that the finely divided powder provided by the process of the invention has the function of acting as an enteric coated product, Test Example 12 The solid dispersions obtained in Example 7 and Comparative Example 3 were subjected to powder X-ray diffraction analysis, As shown in Fig, 9, the patterns showed the disappearance of peaks of oxybutynin hydrochloride crystals which had been observed with the bulk powder and a 1:1 physical mixture, Test Example 13 The solubility of the solid dispersions prepared in Example 7 and Comparative Example 3 were determined, As shown in Table 3, there was found an approximately 3-fold increase in solubility as compared with the bulk substance, This solubility .value approximated that of the solid dispersion prepared by the solvent process in Comparative Example 3.
Table 3 Comparative Example 7 Example 3 Compounding ratio (oxybutynin hydrochloride:A90AT) 1:5 1:5 Solubility of oxybutynin hydrochloride in solid 473.4 490.1 dispersion (,u g/ml) (1) Solubility of oxybutynin hydrochloride bulk 162.5 162.5 substance( ,u g/ml) (2) Solubility ratio [(1)/(2)~ 2.9 3.0 Test method: Saturation dissolution method Test conditions: Constant-temperature bath (25 C) Monocin (24-hr shaking, 24 cycles/min.) JP Test Solution 2 Ultracentrifugation: 40000 rpm x 1 hr; the supernatant analyzed by HPLC.
The results of Test Examples 11, 12 and 13 indicate that the extrudate containing oxybutynin hydrochloride retains the fundamental properties of an enteric coated product and, yet, has been converted to a solid dispersion, Test Example 14 The release test was carried out with the solid dispersions prepared in Example 8 and Comparative Example 4. As shown in Fig, 10, there was no release of nicardipine hydrochloride in JP
Test Solution 1 (pH 1.2). On the other hand, a quick release was obtained in JP Test Solution 2 (pH 6.8).
The above results indicated that the finely divided powder according to the process of the invention has the function of acting as an enteric coated product.
Test Example 15 The solid dispersions obtained in Example $ and Comparative Example 4 were subjected to powder K-ray diffraction analysis, As shown in Fig, 11, the patterns showed the disappearance of peaks of nicardipine hydrochloride crystals which had been observed with the bulk powder and a 1:1 physical mixture.
Test Example 16 The solubility of the solid dispersions prepared in Example $
and Comparative Example 4 were determined, As shown in Table 4, there was found an approximately 6-fold increase in solubility as compared with the bulk substance, This solubility value approximated that of the solid dispersion prepared by the solvent process in Comparative Example 4.
Table 4 Comparative Example 8 Example 4 Compounding ratio (nicardipine hydrochloride:A90AT) 1:5 1~5 Solubility of nicardipine hydrochloride in solid dispersion(, g/ml) (1) 52.6 47. 6 Solubility of nicardipine hydrochloride bulk 8.5 8.5 substance (,u g/ml) (2) Solubility ratio [(1)/(2)~ 6.2 5.6 Test method: Saturation dissolution method Test conditions: Constant-temperature bath (25C) Monocin (24-hr shaking, 24 cyc les/min,) JP Test Solution 2 Oltracentrifugation: 40000 rpm x 1 hr; the supernatant analyzed by HPLC.
The results of Test Examples 14~ 15 and indicate that 16 the extrudate containing nicardipine hydrochlorideretains the fundamental properties of an enteric coated product and, yet, has been converted to a solid dispersion, Test Example 17 The release test was carried out with the solid dispersions prepared in Example 9 and Comparative Example 5. As shown in Fig, 12~ there was no release of diclofenac sodium in JP Test Solution 1 (PH 1.2). On the other hand, a quick release was obtained in JP Test Solution 2 (PH 6.8).
The above results indicated that the finely divided powder according to the process of the invention has the function of acting as an enteric coated product, Test Example 18 The solid products obtained in Example 9 and Comparative Example 5 were subjected to powder H-ray diffraction analysis, As shown in Fig, 13. the patterns showed the disappearance of peaks of diclofenac sodium crystals which had been observed with the bulk powder and a 1:l Physical mixture, The results of Test Examples 17 and l8~indicate that the extrudate containing diclofenac sodium retains the fundamental properties of an enteric coated product and, yet, has been converted to a solid dispersion.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 shows the results of a release test with solid dispersions. The curve up to 180 minutes following the beginning of the test represents the result generated with JP Test Solution 1 (PH 1.2) and the curve after 180 minutes following the beginning of the test represents the result obtained with JP Test Solution 2 (PH 6.8). The time (in minutes) is plotted on the abscissa and the release rate (~) of Compound A is plotted on the ordinate, In the figure, ~ represents the release curve of the solid dispersion obtained in Example 1 and D represents the release curve of the solid dispersion obtained in Comparative Example 1, Fig, 2 shows the results of powder x-ray diffraction analysis of Compound A-containing solid dispersions, The uppermost powder X-ray diffraction pattern represents the X-ray diffraction pattern of the solid dispersion obtained in Example 1; the second powder K-ray diffraction pattern as reckoned from the top is the K-ray diffraction pattern of the solid dispersion obtained in Comparative Example 1; the third powder X-ray diffraction pattern as reckoned from the top is the K-ray diffraction pattern of a physical 1:5 mixture of Compound A and hydroxypropyl-methylcellulose acetate succinate (A90AT, AS-MF grade) (Compound A:A90AT = the same as used in Example 1 and Comparative Example 1) and the downmost powder H-ray diffraction pattern is the X-ray diffraction pattern of Compound A bulk substance. The diffraction angle ( 2 B ) is plotted on the abscissa and the diffraction intensity (CPS) on the ordinate, Fig, 3 shows the results of a release test with indomethacin-containing solid dispersions prepared in Example 2. The time (in minutes) is plotted on the abscissa and the release rate (~) of indomethacin is plotted on the ordinate.
Fig. 4 shows the results of powder X-ray diffraction analysis of indomethacin-containing solid dispersions. The uppermost powder X-ray diffraction pattern represents the X-ray diffraction pattern of the solid dispersion obtained in Example 2; the second powder X-ray diffraction pattern as reckoned from the top is the X-ray diffraction pattern of a 1:5 solid dispersion of indomethacin and hydroxypropylmethylcellulose phthalate (HPMCP, HP-55F grade) (indomethacin:HPMCP = the same as used in Example 2) prepared by the so-called solvent process; the third powder X-ray diffraction pattern as reckoned from the top is the K-ray diffraction pattern of a physical 1:5 mixture of indomethacin and HPMCP (indomethacin:HPMCP = the same as used in Example 2); and the downmost powder X-ray diffraction pattern is the X-ray diffraction pattern of indomethacin bulk substance. The diffraction angle (2 B ) is plotted on the abscissa and the diffraction intensity (CPS) on the ordinate.
Fig. 5 shows the results of a release test with indomethacin-containing solid dispersions prepared in Example 5 in JP Test Solution 1 (PH 1.2). The time (in minutes) is plotted on the abscissa and the release rate (~) of indomethacin is plotted on the ordinate. In the figure, ~ represents the release curve of the solid dispersion obtained by addition of 300 g of wheat starch in Example 5, D represents the release curve of the solid dispersion obtained by addition of 500 g of wheat starch in Example 5 and D represents the release curve of the solid dispersion obtained by addition of 1000 g of wheat starch in Example 5.
Fig. 6 shows the results of a release test with nifedipine-containing solid dispersions prepared in Example 6 and Comparative Example 2. The time (in minutes) is plotted on the abscissa and the release rate (~6) of nifedipine is plotted on the ordinate.
In the figure, represents the release curve of the solid dispersion obtained in Example 6 and D represents the release curve of the solid dispersion obtained in Comparative Example 2.
- ~ 6_ Fig. ; shows the results of powder X-ray diffraction anaiysis of nifedipine-containing solid dispersions. The uppermost powder X-ray diffracticn pattern represents the :x-ray diffraction pattern of the solid dispersion obtained in Example 6; the second powder X-ray diffraction pattern as reckoned from the top is the X-ray diffraction pattern of the solid dispersion obtained in Comparative Example 2; the third powder X-ray diffraction pattern as reckoned from the top is the X-ray diffraction pattern of a physical 1:5 mixture of nifedipine and hydroxypropyl-methylcellulose acetate succinate (A90AT, AS-MF grade) (nifedipine:A90AT = the same as used in Example 6 and Comparative Example 2); and the downmost powder X-ray diffraction pattern is the X-ray diffraction pattern of nifedipine bulk substance, The diffraction angle ( 2 B ) is plotted on the abscissa and the diffraction intensity (CPS) on the ordinate.
Fig, ° shc~;:s the results of a release test with oxybutynin hydrochloride-containing solid dispersions prepared in Example 7 and Comparative Example 3, The time (in minutes) is plotted on the abscissa and the release rate (~) of oxybutynin hydrochloride is plotted on the ordinate.
In the ffigure, represents the release curve of the solid dispersion obtained in Example 7 and 0 represents the release curve of the solid dispersion obtained in Comparative Example 3.
Fig. 9 shows the results of powder X-ray diffraction analysis of oxybutynin hydrochloride-containing solid dispersions. The uppermost powder X-ray diffraction pattern represents the X-ray diffraction pattern of the solid dispersion obtained in Example 7;
the second powder X-ray diffraction pattern as reckoned from the top is the X-ray diffraction pattern of the solid dispersion obtained in Comparative Example 3; the third powder X-ray diffraction pattern as reckoned from the top is the X-ray diffraction pattern of a physical 1:5 mixture of oxybutynin 7 _ hydrochloride and hydroxypropylmethylcellulose acetate succinate (A90AT, AS-MF grade) (oxybutynin hydrochloride:A90AT = the same as used in Example ~ and Comparative Example 3); and the downmost powder K-ray diffraction pattern is the !i-ray diffraction pattern of oxybutynin hydrochloride bulk substance. The diffraction angle (2 B ) is plotted on the abscissa and the diffraction intensity (CPS) on the ordinate, Fig, 10 shows the results of a release test with nicardipine hydrochloride-containing solid dispersions prepared m Example 8 .
and Comparative Example 4. The time (in minutes) is plotted on the abscissa and the release rate (~) of nicardipine hydrochloride is plotted on the ordinate. In the figure, ~ represents the release curve of the solid dispersion obtained in Example 8 and 0 represents the release curve of the solid dispersion obtained in Comparative Example 4.
Fig. 11 shows the results of powder X-ray diffraction analysis of nicardipine hydrochloride-containing solid dispersions. The uppermost powder X-ray diffraction pattern represents the x-ray diffraction pattern of the solid dispersion obtained in Example $; the second powder X-ray diffraction pattern as reckoned from the top is the K-ray diffraction pattern of the solid dispersion obtained in Comparative Example 4; the third powder X-ray diffraction pattern as reckoned from the top is the x-ray diffraction pattern of a physical 1:5 mixture of nicardipine hydrochloride and hydroxypropylmethylcellulose phthalate (HPMCP, HP-55F grade) (nicardipine hydrochloride:HPMCP
- the same as used in Example $ and Comparative Example 4); and the downmost powder X-ray diffraction pattern is the X-ray diffraction pattern of nicardipine hydrochloride bulk substance.
The diffraction angle (2 B ) is plotted on the abscissa and the diffraction intensity (CPS) on the ordinate, . . _ . .y...y Fig. 12 shows the results of a release test with diclofenac sodium-containing solid dispersions prepared in Example 9 and Comparative Example 5. The time (in minutes) is plotted on the abscissa and the release rate (~) of diclofenac sodium is plotted on the ordinate, In the figure, 1 represents the release curve of the solid dispersion obtained in Example 9 and 0 represents the release curve of the solid dispersion obtained in Comparative Example 5.
Fig, 13 shows the results of powder K-ray diffraction analysis of diclofenac sodium-containing solid dispersions. The uppermost powder X-ray diffraction pattern represents the K-ray diffraction pattern of the solid dispersion obtained in Example 9;
the second powder K-ray diffraction pattern as reckoned from the top is the X-ray diffraction pattern of the solid dispersion obtained in Comparative Example 5; the third powder H-ra~~
diffraction pattern as reckoned from the top is the X-ray diffraction pattern of a physical 1:5 mixture of diclofenac sodium and hydroxypropylmethylcellulose phthalate (HPMCP, HP-55F
grade) (diclofenac sodium:HPhICP = the same as used in Example 9 and Comparative Example 5); and the downmost powder X-ray diffraction pattern is the !i-ray diffraction pattern of diclofenac sodium bulk substance. The diffraction angle (2 B ) is plotted on the abscissa and the diffraction intensity (CPS) on the ordinate.
METHOD OF MANUFACTURING OF SOLID DISPERSION
TECHNICAL FIELD
The present invention relates to a process for producing a solid dispersion, More particularly, the invention relates to a process for producing a solid dispersion utilizing a twin-screw extruder, which finds application chiefly in the field of pharmaceutical manufacture.
The term 'solid dispersion' is used herein to mean a drug-containing pharmaceutical bulk substance comprising the drug dissolved or dispersed in a polymer.
BACKGROUND ART
Solid dispersions are of use for an enhanced solubility of drugs or for controlling the rate of release of a drug from a dosage form or improving the bioavailability of drugs, thus being of significant commercial value.
The conventional technology for the production of a solid dispersion includes a fusion process which is characterized by melting a drug and a polymer together at elevated temperature and, then, cooling the melt to solidify, a solvent process which is characterized by dissolving a drug and a polymer in an appropriate solvent and, then, removing the solvent, and a fusion-solvent process which has the characteristics of said processes, However, the fusion process has the disadvantage that it cannot be applied to a drug or polymer which is, or is likely to be, thermally degraded, The solvent process is free from the above-mentioned disadvantage of the fusion process but because it employs an organic solvent such as an alcohol or a chlorine-containing solvent, this process has the following disadvantages, (1) When an alcohol is used as the solvent, strict measures must be provided for the prevention of an explosion hazard during production, 2~~$~'~5 (2) Since organic solvents have fairly high affinities for the polymer, they cannot be easily removed from the product solid dispersions, (3) Removal of the solvent necessarily results in its diffusion into the atmosphere to cause an atmospheric pollution, (4) After removal of the solvent, the solid dispersion adhering intimately to the vessel wall cannot be easily withdrawn from the vessel, DISCLOSURE OF INVENTION
The object of the present invention is to establish an improved process for producing a solid dispersion which has overcome the above-mentioned inherent disadvantages of the fusion and solvent processes, The substantive feature of the present invention resides in the processing of the drug, polymer and other components for a solid dispersion by utilizing a twin-screw extruder, The present invention is now described in detail, The twin-screw extruder is a forward-discharge extruder-granulator characterized by the use of a couple of screws, which differentiate the machine from the so-called single-screw extruder, To be more specific, the twin-screw extruder comprises a metering feeder unit, a barrel (cylinder), screws, paddle means, screw shafts, barrel heater-cooler means, exit dies (cooling die, heating die, molding die) and extrudate cutter and provides for a free variation of compounding pressure and molding temperature through a choice of screw geometry, rotational speed, and screw elements to be mounted on the screw shafts, Furthermore, if necessary, the barrel can be used in a variety of combinations of length and type according to the intended use and its temperature can also be controlled as desired, Thus, the twin-screw extruder processes the feed with two screws and provides for change of the combination of axial screw elements so that it has many definite advantages over the single-screw extruder, viz, (1) In the twin-screw extruder, the respective screws influence each other so that the material is not rotated together with the screws and, hence, the compounding is not much influenced by characteristics of the material, Therefore, the twin-screw extruder is capable of processing an oil-rich or water-rich material which cannot be successfully processed by the single-screw extruder.
(2) Compared with the single-screw extruder, the twin-screw extruder is by far superior in shear force, compounding effect and transport capacity, Therefore, in the processing of a protein, for instance, the structurization of the protein which cannot be achieved with the single-screw extruder can be accomplished with the twin-screw extruder, (3) The twin-screw extruder features a minimum heat of friction of the barrel and is, therefore, conducive to the ease of temperature control, As a consequence, the twin-screw extruder is more suited for pharmaceuticals which are vulnerable to high temperature, The polymer to be used in the present invention can be virtually any natural or synthetic polymer that can be generally used as a raw material in the manufacture of pharmaceutical products and such that its functions are not adversely affected by the passage through the small die orifice or orifices of the twin-screw extruder, Among such polymer are pH-dependent polymers, pH-independent polymers and water-soluble polymers, for instance, and specifically include the following, Hydroxypropylmethylcellulose phthalate 220824 (HP50)~
hydroxypropylmethylcellulose phthalate 220'731 (HP55), hydroxypropylmethylcellulose acetate succinate (A90AT), carboxymethylethylcellulose (CMEC), cellulose acetate phthalate (CAP), methacrylic copolymer LD (L30D55), methacrylic copolymer S
(S-100), aminoalkyl methacrylate copolymer E (gastric coating base), polyvinyl acetal) diethylaminoacetate (AEA), polyvinylpyrrolidone (K-25, 30, 90~ PVP), ethylcellulose (EC), methacrylic copolymer RS (RS 30D), polyvinyl alcohol (PVA), methylcellulose (MC), hydroxypropylcellulose (HPC), hydroxypropylmethylcellulose 2208 (Metolose 90SH), hydroxypropylmethylcellulose 2906 (Metolose 65SH), hydroxypropylmethylcellulose 2910 (Metolose 60SH), carboxymethylcellulose sodium (sodium cellulose glycolate), dextrin, pullulan, Acacia, tragacanth, sodium alginate, propylene glycol alginate, agar powder, gelatin, starch, processed starch, phospholipids (lecithin), glucomannan and so on, The polymers can be used independently or, if necessary, in a combination of two or more species, The particle diameter of said polymer need not necessarily be finer that the size which can be fed from the hopper to the body of the twin-screw extruder and is generally not greater than 7000 a m and preferably not greater than 2000 ,u m, Coarser polymers can also be used by comminuting them beforehand, The processing parameters such as pressure, temperature, feed rate of material, amounts and feed rates of water, plasticier and other additives in the production process of the present invention are dependent on the type of drug and of polymer, the twin-extruder model used and other conditions but it is important to select a combination of parameters such that the drug, polymer, etc. will be maintained at temperatures below their decomposition points and vary the operating parameters according to the desired characteristics of the product, The compounding ratio of the drug to the polymer should vary with the species of drug and of polymer, the objective, film characteristics and so on, Based on each part of the drug, the proportion of the polymer is generally 0.1 to 999 parts, preferably 0.5 to 500 Parts and for still better results, 1 to 50 parts, When the system contains a thermally labile drug and/or polymer, an aqueous solution or dispersion of a plasticizer may be added to the material prior to feeding to the twin-screw extruder or during compounding. Since this practice lowers the transition temperature of the polymer, the molding temperature setting can then be lower than the decomposition points of the drug and polymer to prevent thermal degradation of the drug and polymer. Of course, an aqueous plasticizer solution or dispersion may be added in the same manner when no heat-labile drug or polymer is contained in the system, As the plasticizer which can be used for depressing the transition temperature of the polymer, those compounds which are generally used as plasticizers for film coating compositions in the pharmaceutical field can be mentioned, For example, the following compounds can be mentioned, Cetanol, medium chain triglycerides, polyoxyethylene-polyoxypropylene glycol (Pluronic), macrogols (200, 300 400 1000. 1500. 1540. 4000, 6000, 20000) triacetin, triethyl citrate (Citroflex), etc, It should be understood that the plasticizes which can be used in the present invention is not limited to the species mentioned above but can be any compound having the property to lower the transition temperature of the polymer, The level of addition of said plasticizes is dependent on the types of drug and polymer used but is appropriately 1 to 80~ and preferably 5 to 5096 relative to the polymer, The method for addition of the plasticizes may be direct addition to the system containing the polymer and the drug before compounding or addition of an aqueous solution or dispersion of the plasticizes in the course of molding, There is no particular limitation on the method~of addition, The drug which can be used in the present invention is not particularly limited but is preferably a non-heat-labile drug, particularly a drug which is not decomposed at any temperature not exceeding 50°C. As such drugs, there can be mentioned the following, among others, 1. Antipyretic, analgesic and antiinflammatory agents Indomethacin, aspirin, diclofenac sodium, ketoprofen, ibuprofen, mefenamic acid, dexamethasone, dexamethasone sodium sulfate, hydrocortisone, prednisolone, azulene, phenacetin, isopropylantipyrine, acetaminophen, benzydamine hydrochloride, phenylbutazone, flufenamic acid, sodium salicylate, choline salicylate, Sasapyrine (salsalate), clofezone, etodolac, 2. Antiulcer agents Sulp hide, cetraxate hydrochloride, gefarnate, i irsogladine maleate, cimetidine, ranitidine hydrochloride, famotidine, nizatidine, roxatidine acetate hydrochloride.
3. Coronary vasodilators Nifedipine, isosorbide dinitrate, diltiazem hydrochloride, trapidil, dipyridamole, dilazep dihydrochloride, methyl 2,6-dimethyl-4-(2-nitrophenyl)-5-(2-oxo-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydropyridine-3-carboxylate, verapamil, nicardipine, nicardipine hydrochloride, verapamil hydrochloride, 4. Peripheral vasodilators Ifenprodil tartrate, cinepazide maleate, cyclandelate, cinnarizine, pentoxiphylline.
5. Antibiotics Ampicillin, amoxicillin, cefalexin, erythromycin ethyl succinate, bacampicillin hydrochloride, minocycline hydrochloride, chloramphenicol, tetracycline, erythromycin, 6. Synthetic antimicrobial agents Nalidixic acid, piromidic acid, pipemidic acid trihydrate, enoxacin, cinoxacin, ofloxacin, norfloxacin, ciprofloxacin hydrochloride, sulfamethoxazole-trimethoprim, 6-fluoro-1-methyl-7-[4-(5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl-1-piperazinyl]-4-oxo-4H[1,3]-thiazeto[3,2-a]quinoline-3-carboxylic acid, _7_ Antispasmodic agents Propantheiine bromide, ,.:ropine sulfate, ~xapmm bromide, timepidium bromide, scopolamine butylbromide, trospium chloride, butropium bromide, ~f-methylscopolamine methyisulfate, octatropine methylbromide.
Antitussm a and antiasthmatic agents iheophylline, aminophyiline, methylephedrine hydrochloride, procaterol hydrochloride, trimethoquinol hydrochloride, codeine phosphate, cromoglicate sodium, tranilast, dextromethorphan hydrobromide, dimemorfan phosphate, clobutinol hydrochloride, tominoben hydrochloride, benproperine phosphate, tipepidine hibenzate, eprazinone hydrochloride, clofedanol hydrochloride, ephedrine hydrochloride, noscapine, carbetapentane citrate, oxeladin tannate, isoaminile citrate, 9. Bronchodilators Diprophylline, salbutamol sulfate, clorprenaline hydrochloride, formoterol fumarate, orciprenaline sulfate, pirbuterol hydrochloride, hexoprenaline-sulfate, bitolterol mesilate, clenbuterol hydrochlo'~ide, terbutaline sulfate, mabuterol hydrochloride, fenoterol hydrobromide,.methoxyphenamine hydrochloride.
Diuretics Furosemide, acetazoiamide, trichlormethiazide, cyclothiazide, hydrochlorothiazide, hydroflumethiazide, ethiazide, cyclopentiazide, spironolactone, triamterene, chlorothiazide, ;i~ -g,-piretanide, mefruside, atacrynic ~ciG, azosemide, cicienamide, 11. Muscle relaxants Chlorophenesin carbamate, toiperisone hydrochloride, eperisone hydrochloride, tizanidine hydrochloride, mephenesin, chlorzoxazone, phenprodamate, methocarbamoi, chlormeza~none, pridinoi mesiiate, aiioqualone, ;;aclofen, cant;ciene sodium 12. Cerebral metabolism Improving agents ~leciofenoxate hydrochloride.
13. Minor tranquilizers Oxazolam, diazepam, clotiazepam, medazepam, temazepam, fludiazepam, meprobamate, nitrazepam, chlordiazepoxide.
19. 'Major tranquilizers Su~piride, clocapramine hydrochloride, zotepine, chloropromazine, haloperidol.
15. ,~ -Elockers Pindolol, propranolol hydrochloride, carteolol hydrochloride, metoprolol tartrate, labetalol hydrochloride, oxprenolol hydrochloride, acebutolol hydrochloride, bufetolol hydrochloride, alprenolol hydrochloride, arotinolol hydrochloride, nadolol, bucumolol hydrochloride, indenolol hydrochloride, timolol maleate, befunolol hydrochloride.
A
16. ,4ntiarrhythmic agents Procainamide hydrochloride, disopyramide, a~maline, quinidine sulfate, aprindine hydrochloride, propafenone hydrochloride, mexiletine hydrochloride, Antigout agents ~llopurinol, probeneci;:, ..cichicme, suifinpyrazone, benzbromarone, bucolome, 18. Anticoagulants Ticlopidine hydrochloride, dicoumarol, warfarin potassium.
Antiepiieptics Phenytoin, sodium vaiproate, metharbital, carbamazepine.
20. Antihistaminics Chlorpheniramine maleate, clemastine fumarate, mequitazine, alimemazine tartrate, cyproheptadine hydrochloride, 21. Antiemetics Difenidol hydrochloride, metoclopramide, domperidone, betahistine m~s::~;:, trimebutine maleate, 22. Antihypertensive agents Dimethylaminoethyl reserpilinate hydrochloride, rescinnamine, methyldopa, prazosin hydrochloride, bunazosin hydrochloride, clonidine hydrochloride, budralazine, urapidil, 23. Sympathomimetic agents Dihydroergotamine mesilate, isoproterenol hydrochloride, etilefrine hydrochloride.
2a_, expectorants Bromhexine hydrocnioriae, carbocystem e, system a ethyl ester hydrochloride, system a methyl ester hydrochloride, 25. Ural antidiabetic agents Glibenclamide, tolbutamide, glymidine sodium, 26. ~.ardicvascular system drugs l:bidecarenone, ATP 2;Va.
2~_ Iron preparations Ferrous sulfate, dried iron sulfate.
2g. Vitamins Vitamin B,, vitamin B2, vitamin Be, vitamin 8,~, vitamin C, folic acid, 29. Therapeutic agents for pollakiuria Flavoxate hydrochloride, oxybutynin hydrochloride, terodiline hydrochloride, ~-diethylamino-1,1-dimethyl-2-butynyl (+)-a -cyclohexyl-a -phenylglycolate hydrochloride monohydrate.
30. ~'n8iotensin converting enzyme inhibitors Enalapril maleate, alacepril, delapril hydrochloride, The solid dispersion prepared according to the invention can be easily comminuted using an appropriate mill or the like to provide a finely divided solid dispersion, which can be directly utilized as powders or granules, It can also be processed into a variety of dosage forms for oral administration, such as tablets, granules, fine granules, capsules, semi-solid dispersion-filled capsules, oily substance-filled capsules and so on, -1 l In October 1991, a technology for the manufacture of a controlled release dosage form utilizing a single-screw extruder was disclosed (CapsuleNews, June/July, Vol. 1, No. 3. Warner-Lambert Co,), However, the technology disclosed in the above literature is a process using a single-screw extruder which is by far interior to the twin-screw extruder as pointed out hereinbefore and the product is also distinct from the solid dispersion provided by the process of the present invention, Furthermore, the above technology is intended for the manufacture of a slow release dosage form and this slow release dosage farm is manufactured at high temperature, Therefore, the above technology is irrelevant to the process of the invention which is intended for the manufacture of a solid dispersion overcoming the disadvantages of the prior art fusion and solvent processes, EFFECTS OF INVENTION
In accordance with the present invention, a solid dispersion can be provided without exposing the drug and polymer to high temperature and without use of any organic solvent, In accordance with the invention, a solid dispersion can be molded and taken out in a pure form and a solid dispersion of any desired size and shape can be manufactured by varying the discharge die orifice diameter and configuration, Furthermore, other disadvantages of the fusion and solvent processes are successfully obviated, BEST MODE OF PRACTICING THE INVENTION
The following examples, comparative Examples and Test Examples are intended to describe the present invention in further detail, Example 1 Five-hundred (500) grams of Compound A (compound name: methyl 2, 6-dimethyl-4-(2-nitrophenyl)-5-(2-oxo-1, 3, 2-dioxaphosphorinan-2-yl)-1,4-dihydropyridine-3-carboxylate; the same applies hereinafter) was pulverized and this bulk powder (mean particle diameter: 60 ~ m) was blended with 2500 g of hydr-oxypropylmethylcellulose acetate succinate (tradename: A90AT, AS-MF, Shin-etsu Chemical; the same applies hereinafter), Then, while a small quantity of water was added, the mixture was processed using a twin-screw extruder (KEX-30, Kurimoto Iron Works; the same applies hereinafter) equipped with a 4 mm ~ x 2-orifice die at a barrel temperature of 100 °C and an extrusion speed of 200 rpm to provide an extrudate (solid dispersion), This extrudate was pulverized in a sample mill (Model AP-S, Hosokawa Iron Works; the same applies hereinafter) and the finely-divided powder thus obtained was used as samples for the release test (65-100 mesh), power K-ray diffraction analysis (250 mesh pass) and solubility (65-100 mesh).
Example 2 Five-hundred (500) grams of indomethacin was blended with 2500 g of hydroxypropylmethylcellulose phthalate (tradename:
HPMCP, HP-55F grade, Shin-etsu Chemical; the same applies hereinafter), and while a 5096 (w/w) aqueous solution of triethyl citrate was added, the composition was molded using a twin-screw extruder equipped with a 4 mm ~ x 2-orifice die at a barrel temperature of $0°C and an extrusion speed of 200 rpm to provide an extrudate (solid dispersion), This extrudate was comminuted in a sample mill and the resulting finely divided powder was used as samples for the release test, powder X-ray diffraction analysis and solubility, Example 3 Five-hundred (500) grams of indomethacin was blended with 1500 g of polyvinyl acetal) diethylaminoacetate (trademark: AEA, Sankyo Organic Chemicals) and while a 5096 (w/w) aqueous solution of triacetin was added, the composition was molded using a twin-screw extruder equipped with a 4 mm ~ x 2-orifice die at a barrel temperature of 90°C and an extrusion speed of 200 rpm to provide an extrudate (solid dispersion), Example 4 Two-hundred (200) grams of Compound B (compound name: 4-diethylamino-l,l-dimethyl-2-butynyl (+)- a -cyclohexyl-a -phenyl-glycolate hydrochloride monohydrate) was blended with 1600 g of methacrylic copolymer LD (tradename: Eudragit, grade L30D55, available from K.K. Higuchi Shokai) and 200 g of wheat starch, Then, while water was added (poured), the composition was molded using a twin-screw extruder equipped with a ø mm~ x 2-orifice die at a barrel temperature of 100 °C and an extrusion speed of 200 rpm to provide an extrudate (solid dispersion), Example 5 Two-thousand (2000) grams of a 1:1 (w/w) mixture of indomethacin and ethyl cellulose (tradename: Ethocel, STD-45 type, Dow Chemical,) was weighed out and wheat starch was added at the three levels of 300 g, 500 g and 1000 g. While a 596 (w/w) aqueous solution of triacetin was added at the rate of 5 ml/min,, each of the above mixtures was molded using a twin-screw extruder equipped with 4 mm ~ x 2-orifice die at a barrel temperature of 80°C and an extrusion speed of 200 rpm to provide an extrudate (solid dispersion), Each of these extrudates was pulverized in a sample mill and the resulting finely divided powder (65-100 mesh) was used as test samples.
Example 6 Three-hundred (300) grams of nifedipine was blended with 1500 g of hydroxypropylmethylcellulose acetate succinate and while water was added, the composition was molded using a twin-screw extruder equipped with 4 mm ~ x 2-orifice die at a barrel temperature of 100 °C and an extrusion speed of 200 rpm to provide an extrudate (solid dispersion).
This extrudate was pulverized in a sample mill and the resulting finely divided powder was used as samples for the release test (65-100 mesh), power x-ray diffraction analysis (250 mesh pass) and solubility (65-100 mesh).
Example 7 Two-hundred (200) grams of oxybutynin hydrochloride was blended with 1000 g of hydroxypropylmethylcellulose acetate succinate and while water was added, the composition was molded using a twin-screw extruder equipped with 2 mm ~ x 3-orifice die at a barrel temperature of 100 °C and an extrusion speed of 200 rpm to provide an extrudate (solid dispersion).
This extrudate was pulverized in a sample mill and the resulting finely divided powder was used as samples for the release test (65-100 mesh), power X-ray diffraction analysis (250 mesh pass) and solubility (65-100 mesh).
Example 8 Two-hundred (200) grams of nicardipine hydrochloride was blended with 1000 B of hydroxypropylmethylcellulose phthalate and while a 50~ (w/w) aqueous solution of propylene glycol was added, the composition was molded using a twin-screw extruder equipped with 2 mm ~ x 3-orifice die at a barrel temperature of 80°C and an extrusion speed of 200 rpm to provide an extrudate (solid dispersion), This extrudate was pulverized in a sample mill and the resulting finely divided powder was used as samples for the release test (65-100 mesh), power X-ray diffraction analysis (250 mesh pass) and solubility (65-100 mesh).
Example 9 Five-hundred (500) 8rams of diclofenac sodium was blended with 2500 B of hydroxypropylmethylcellulose phthalate and while a 5096 (w/w) aqueous solution of triethyl citrate was added, the composition was molded using a twin-screw extruder equipped with 4 mm~ x 2-orifice die at a barrel temperature of 80°C and an extrusion speed of 150 rpm to provide an extrudate (solid dispersion), This extrudate was pulverized in a sample mill and the resulting finely divided powder was used as samples for the release test (65-100 mesh), power X-ray diffraction analysis (250 mesh pass) and solubility (65-100 mesh).
Comparative Example 1 Solvent Process Five (5) grams of Compound A and 25 g of hydr-oxypropylmethylcellulose acetate succinate were weighed out and dissolved by addition of 700 ml of ethanol and 300 ml of methylene chloride, Then, using a rotary evaporator, the solvent was thoroughly evaporated at 5p °C to provide a solid (solid dispersion), This solid was pulverized in a table-top compact mill and the resulting fine powder was size-selected to provide comparative test samples for the release test (65-100 mesh), powder K-ray diffraction analysis (250 mesh pass) and solubility test (65-100 mesh).
Comparative Example 2 Nc W SflEt T
Five (5) grams of nifedipine and 25 g of hydr-oxypropylmethylcellulose acetate succinate were weighed out and dissolved by addition of 700 ml of ethanol and 300 ml of methylene chloride, Then, using a rotary evaporator, the solvent was thoroughly evaporated at 50 °C to provide a solid (solid dispersion). This solid was pulverized in a table-top compact mill and the resulting fine powder was size-selected to provide comparative test samples for the release test (65-100 mesh), powder X-ray diffraction analysis (250 mesh pass) and solubility test (65-100 mesh).
Comparative Example 3 Five (5) grams of oxybutynin hydrochloride and 25 g of hydroxypropylmethylcellulose acetate succinate were weighed out and dissolved by addition of 700 ml of ethanol and 300 ml of methylene chloride. Then, using a rotary evaporator, the solvent was thoroughly evaporated at 50°C to provide a solid (solid dispersion). This solid was pulverized in a table-top compact mill and the resulting fine powder was size-selected to provide comparative test samples for the release test (65-100 mesh), powder K-ray diffraction analysis (250 mesh pass) and solubility test (65-100 mesh).
Comparative Example 4 Five (5) grams of nicardipine hydrochloride and 25 g of hydroxypropylmethylcellulose phthalate were weighed out and dissolved by addition of 700 ml of ethanol and 300 ml of methylene chloride. Then, using a rotary evaporator, the solvent was thoroughly evaporated at 50 °C to provide a solid (solid dispersion). This solid was pulverized in a table-top compact mill and the resulting fine powder was size-selected to provide comparative test samples for the release test (65-100 mesh), powder X-ray diffraction analysis (250 mesh pass) and solubility test (65-100 mesh), Comparative Example 5 Five (5) grams of diclofenac sodium and 25 g of hydroxypropylmethylcellulose phthalate were weighed out and dissolved by addition of 700 ml of ethanol and 300 ml of methylene chloride, Then, using a rotary evaporator, the solvent was thoroughly evaporated at 50 °C to provide a solid (solid dispersion). This solid was pulverized in a table-top compact mill and the resulting fine powder was size-selected to provide comparative test samples for the release test (65-100 mesh) and powder X-ray diffraction analysis (250 mesh pass), Test Example 1 The release test was carried out with the solid dispersions prepared in Example 1 (extruded product) and Comparative Example 1. As shown in Fig, 1, there was no release of Compound A under the conditions of JP Test Solution 1 (pH 1.2). 900 ml test solution and paddle speed 100 rpm. On the other hand, a quick release was obtained under the conditions of JP Test Solution 2 (pH 6.8), 900 ml test solution and paddle speed 100 rpm.
The above results indicated that the finely divided powder according to the process of the invention has the function of acting as an enteric coated product, Test Example 2 The solid products obtained in Example 1 and Comparative Example 1 were subjected to powder K-ray diffraction analysis, As shown in Fig, 2, the results showed the disappearance of peaks of Compound A crystals which had been observed with the bulk powder and a 1:1 physical mixture.
Test Example 3 The solubility of the test sample prepared in Example 1 was determined, As shown in Table 1, there was found an approximately 4-fold increase in solubility as compared with the bulk substance, This solubility value approximated that of the solid dispersion prepared by the solvent process in Comparative Example 1.
Table 1 Comparative Example 1 Example 1 Compounding ratio (Compound A:A90AT) 1:5 1:5 Solubility of Compound A in solid dispersion (,u g/ml)(1) 155 146 Solubility of Compound A
bulk substance ( ,u g/ml) (2) 36. 5 36. 5 Solubility ratio [(1)/(2)7 4.2 4.0 Test method: Saturation dissolution method Test conditions: Constant-temperature bath (25°C) Monocin (24-hr shaking, 24 cycles/min. ) JP Test Solution 2 Ultracentrifugation: 40000 rpm x 1 hr; the supernatant analyzed by HPLC, The results of Test Examples 1, 2 and 3 indicate that the extrudate retains the fundamental properties of an enteric coated product and, yet, has been converted to a solid dispersion, Test Example 4 The release test was carried out with the sample prepared in Example 2. As shown in Fig. 3, there was no release of indomethacin in JP Test Solution 1 (PH 1.2). On the other hand, a quick release was obtained in JP Test Solution 2 (pH 6.8).
The above results indicated that the finely divided powder according to the process of the invention has the function of acting as an enteric coated product, Test Example 5 The sample obtained in Example 2 was subjected to powder K-ray diffraction analysis, As shown in Fig, 4, the results showed the disappearance of peaks of indomethacin crystals which had been observed with the bulk powder and a l:l physical mixture, Test Example 6 The solubility of the solid dispersion prepared in Example 2 (extruded product) was determined, There was found an approximately 2-fold increase in solubility as compared with the bulk substance, This solubility value approximated that of the solid dispersion prepared by the solvent process, Test Example 7 The 35 mg indomethacin equivalent of the sample obtained in Example 5 was weighed and added to 900 ml of JP Test Solution 1 (pH 1.2) and the release test was carried out at a paddle speed of 100 rpm using a measuring wavelength of 320 nm, The result shown in Fig, 5 indicates that the release of indomethacin was suppressed and that the rate of release increased with an increasing amount of wheat starch added, Test Example 8 The release test was carried out with the solid dispersions prepared in Example 6 and Comparative Example 2, As shown in Fig, 6, there was no release of nifedipine in JP Test Solution 1 (pH 1.2). On the other hand, a quick release was obtained in JP
Test Solution 2 (PH 6.8).
The above results indicated that the finely divided powder according to the process of the invention has the function of acting as an enteric coated product, Test Example g The solid products obtained in Example 6 and Comparative Example 2 were subjected to powder H-ray diffraction analysis, As shown in Fig, 7, the results showed the disappearance of peaks of nifedipine crystals which had been observed with the bulk powder and a 1:1 physical mixture, Test Example 10 The solubility of the solid products prepared in Example 6 and Comparative Example 2 was determined, As shown in Table 2, there was found an approximately 5-fold increase in solubility as compared with the bulk substance. This solubility value was close to that of the solid dispersion prepared by the solvent process in Comparative Example 2.
Table 2 Comparative Example 6 Example 2 Compounding ratio (Nifedipine:A90AT) 1:5 1:5 Solubility of nifedipine in sol id dispersion ( ,u g/ml) (1) 26. 3 28. 6 Solubility of nifedipine bulk substance ( ,u g/ml) (2) 5. 6 5. 6 Solubility ratio [(1)/(2)~ 4.7 5.1 Test method: Saturation dissolution method Test conditions: Constant-temperature bath (25°C) Monocin (24-hr shaking, 24 cycles/min,) JP Test Solution 2 Ultracentrifugation: 40000 rpm x 1 hr; the supernatant analyzed by HPLC.
The results of Test Examples 8, 9 and 10 indicate that the extrudate containing nifedipine retains the fundamental properties of an enteric coated product and, yet, has been converted to a solid dispersion.
Test Example 11 The release test was carried out with the solid dispersions prepared in Example 7 and Comparative Example 3. As shown in Fig. 8, there was no release of oxybutynin hydrochloride in JP
Test Solution 1 (pH 1.2). On the other hand, a quick release was obtained in JP Test Solution 2 (PH 6.8).
The above results indicated that the finely divided powder provided by the process of the invention has the function of acting as an enteric coated product, Test Example 12 The solid dispersions obtained in Example 7 and Comparative Example 3 were subjected to powder X-ray diffraction analysis, As shown in Fig, 9, the patterns showed the disappearance of peaks of oxybutynin hydrochloride crystals which had been observed with the bulk powder and a 1:1 physical mixture, Test Example 13 The solubility of the solid dispersions prepared in Example 7 and Comparative Example 3 were determined, As shown in Table 3, there was found an approximately 3-fold increase in solubility as compared with the bulk substance, This solubility .value approximated that of the solid dispersion prepared by the solvent process in Comparative Example 3.
Table 3 Comparative Example 7 Example 3 Compounding ratio (oxybutynin hydrochloride:A90AT) 1:5 1:5 Solubility of oxybutynin hydrochloride in solid 473.4 490.1 dispersion (,u g/ml) (1) Solubility of oxybutynin hydrochloride bulk 162.5 162.5 substance( ,u g/ml) (2) Solubility ratio [(1)/(2)~ 2.9 3.0 Test method: Saturation dissolution method Test conditions: Constant-temperature bath (25 C) Monocin (24-hr shaking, 24 cycles/min.) JP Test Solution 2 Ultracentrifugation: 40000 rpm x 1 hr; the supernatant analyzed by HPLC.
The results of Test Examples 11, 12 and 13 indicate that the extrudate containing oxybutynin hydrochloride retains the fundamental properties of an enteric coated product and, yet, has been converted to a solid dispersion, Test Example 14 The release test was carried out with the solid dispersions prepared in Example 8 and Comparative Example 4. As shown in Fig, 10, there was no release of nicardipine hydrochloride in JP
Test Solution 1 (pH 1.2). On the other hand, a quick release was obtained in JP Test Solution 2 (pH 6.8).
The above results indicated that the finely divided powder according to the process of the invention has the function of acting as an enteric coated product.
Test Example 15 The solid dispersions obtained in Example $ and Comparative Example 4 were subjected to powder K-ray diffraction analysis, As shown in Fig, 11, the patterns showed the disappearance of peaks of nicardipine hydrochloride crystals which had been observed with the bulk powder and a 1:1 physical mixture.
Test Example 16 The solubility of the solid dispersions prepared in Example $
and Comparative Example 4 were determined, As shown in Table 4, there was found an approximately 6-fold increase in solubility as compared with the bulk substance, This solubility value approximated that of the solid dispersion prepared by the solvent process in Comparative Example 4.
Table 4 Comparative Example 8 Example 4 Compounding ratio (nicardipine hydrochloride:A90AT) 1:5 1~5 Solubility of nicardipine hydrochloride in solid dispersion(, g/ml) (1) 52.6 47. 6 Solubility of nicardipine hydrochloride bulk 8.5 8.5 substance (,u g/ml) (2) Solubility ratio [(1)/(2)~ 6.2 5.6 Test method: Saturation dissolution method Test conditions: Constant-temperature bath (25C) Monocin (24-hr shaking, 24 cyc les/min,) JP Test Solution 2 Oltracentrifugation: 40000 rpm x 1 hr; the supernatant analyzed by HPLC.
The results of Test Examples 14~ 15 and indicate that 16 the extrudate containing nicardipine hydrochlorideretains the fundamental properties of an enteric coated product and, yet, has been converted to a solid dispersion, Test Example 17 The release test was carried out with the solid dispersions prepared in Example 9 and Comparative Example 5. As shown in Fig, 12~ there was no release of diclofenac sodium in JP Test Solution 1 (PH 1.2). On the other hand, a quick release was obtained in JP Test Solution 2 (PH 6.8).
The above results indicated that the finely divided powder according to the process of the invention has the function of acting as an enteric coated product, Test Example 18 The solid products obtained in Example 9 and Comparative Example 5 were subjected to powder H-ray diffraction analysis, As shown in Fig, 13. the patterns showed the disappearance of peaks of diclofenac sodium crystals which had been observed with the bulk powder and a 1:l Physical mixture, The results of Test Examples 17 and l8~indicate that the extrudate containing diclofenac sodium retains the fundamental properties of an enteric coated product and, yet, has been converted to a solid dispersion.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 shows the results of a release test with solid dispersions. The curve up to 180 minutes following the beginning of the test represents the result generated with JP Test Solution 1 (PH 1.2) and the curve after 180 minutes following the beginning of the test represents the result obtained with JP Test Solution 2 (PH 6.8). The time (in minutes) is plotted on the abscissa and the release rate (~) of Compound A is plotted on the ordinate, In the figure, ~ represents the release curve of the solid dispersion obtained in Example 1 and D represents the release curve of the solid dispersion obtained in Comparative Example 1, Fig, 2 shows the results of powder x-ray diffraction analysis of Compound A-containing solid dispersions, The uppermost powder X-ray diffraction pattern represents the X-ray diffraction pattern of the solid dispersion obtained in Example 1; the second powder K-ray diffraction pattern as reckoned from the top is the K-ray diffraction pattern of the solid dispersion obtained in Comparative Example 1; the third powder X-ray diffraction pattern as reckoned from the top is the K-ray diffraction pattern of a physical 1:5 mixture of Compound A and hydroxypropyl-methylcellulose acetate succinate (A90AT, AS-MF grade) (Compound A:A90AT = the same as used in Example 1 and Comparative Example 1) and the downmost powder H-ray diffraction pattern is the X-ray diffraction pattern of Compound A bulk substance. The diffraction angle ( 2 B ) is plotted on the abscissa and the diffraction intensity (CPS) on the ordinate, Fig, 3 shows the results of a release test with indomethacin-containing solid dispersions prepared in Example 2. The time (in minutes) is plotted on the abscissa and the release rate (~) of indomethacin is plotted on the ordinate.
Fig. 4 shows the results of powder X-ray diffraction analysis of indomethacin-containing solid dispersions. The uppermost powder X-ray diffraction pattern represents the X-ray diffraction pattern of the solid dispersion obtained in Example 2; the second powder X-ray diffraction pattern as reckoned from the top is the X-ray diffraction pattern of a 1:5 solid dispersion of indomethacin and hydroxypropylmethylcellulose phthalate (HPMCP, HP-55F grade) (indomethacin:HPMCP = the same as used in Example 2) prepared by the so-called solvent process; the third powder X-ray diffraction pattern as reckoned from the top is the K-ray diffraction pattern of a physical 1:5 mixture of indomethacin and HPMCP (indomethacin:HPMCP = the same as used in Example 2); and the downmost powder X-ray diffraction pattern is the X-ray diffraction pattern of indomethacin bulk substance. The diffraction angle (2 B ) is plotted on the abscissa and the diffraction intensity (CPS) on the ordinate.
Fig. 5 shows the results of a release test with indomethacin-containing solid dispersions prepared in Example 5 in JP Test Solution 1 (PH 1.2). The time (in minutes) is plotted on the abscissa and the release rate (~) of indomethacin is plotted on the ordinate. In the figure, ~ represents the release curve of the solid dispersion obtained by addition of 300 g of wheat starch in Example 5, D represents the release curve of the solid dispersion obtained by addition of 500 g of wheat starch in Example 5 and D represents the release curve of the solid dispersion obtained by addition of 1000 g of wheat starch in Example 5.
Fig. 6 shows the results of a release test with nifedipine-containing solid dispersions prepared in Example 6 and Comparative Example 2. The time (in minutes) is plotted on the abscissa and the release rate (~6) of nifedipine is plotted on the ordinate.
In the figure, represents the release curve of the solid dispersion obtained in Example 6 and D represents the release curve of the solid dispersion obtained in Comparative Example 2.
- ~ 6_ Fig. ; shows the results of powder X-ray diffraction anaiysis of nifedipine-containing solid dispersions. The uppermost powder X-ray diffracticn pattern represents the :x-ray diffraction pattern of the solid dispersion obtained in Example 6; the second powder X-ray diffraction pattern as reckoned from the top is the X-ray diffraction pattern of the solid dispersion obtained in Comparative Example 2; the third powder X-ray diffraction pattern as reckoned from the top is the X-ray diffraction pattern of a physical 1:5 mixture of nifedipine and hydroxypropyl-methylcellulose acetate succinate (A90AT, AS-MF grade) (nifedipine:A90AT = the same as used in Example 6 and Comparative Example 2); and the downmost powder X-ray diffraction pattern is the X-ray diffraction pattern of nifedipine bulk substance, The diffraction angle ( 2 B ) is plotted on the abscissa and the diffraction intensity (CPS) on the ordinate.
Fig, ° shc~;:s the results of a release test with oxybutynin hydrochloride-containing solid dispersions prepared in Example 7 and Comparative Example 3, The time (in minutes) is plotted on the abscissa and the release rate (~) of oxybutynin hydrochloride is plotted on the ordinate.
In the ffigure, represents the release curve of the solid dispersion obtained in Example 7 and 0 represents the release curve of the solid dispersion obtained in Comparative Example 3.
Fig. 9 shows the results of powder X-ray diffraction analysis of oxybutynin hydrochloride-containing solid dispersions. The uppermost powder X-ray diffraction pattern represents the X-ray diffraction pattern of the solid dispersion obtained in Example 7;
the second powder X-ray diffraction pattern as reckoned from the top is the X-ray diffraction pattern of the solid dispersion obtained in Comparative Example 3; the third powder X-ray diffraction pattern as reckoned from the top is the X-ray diffraction pattern of a physical 1:5 mixture of oxybutynin 7 _ hydrochloride and hydroxypropylmethylcellulose acetate succinate (A90AT, AS-MF grade) (oxybutynin hydrochloride:A90AT = the same as used in Example ~ and Comparative Example 3); and the downmost powder K-ray diffraction pattern is the !i-ray diffraction pattern of oxybutynin hydrochloride bulk substance. The diffraction angle (2 B ) is plotted on the abscissa and the diffraction intensity (CPS) on the ordinate, Fig, 10 shows the results of a release test with nicardipine hydrochloride-containing solid dispersions prepared m Example 8 .
and Comparative Example 4. The time (in minutes) is plotted on the abscissa and the release rate (~) of nicardipine hydrochloride is plotted on the ordinate. In the figure, ~ represents the release curve of the solid dispersion obtained in Example 8 and 0 represents the release curve of the solid dispersion obtained in Comparative Example 4.
Fig. 11 shows the results of powder X-ray diffraction analysis of nicardipine hydrochloride-containing solid dispersions. The uppermost powder X-ray diffraction pattern represents the x-ray diffraction pattern of the solid dispersion obtained in Example $; the second powder X-ray diffraction pattern as reckoned from the top is the K-ray diffraction pattern of the solid dispersion obtained in Comparative Example 4; the third powder X-ray diffraction pattern as reckoned from the top is the x-ray diffraction pattern of a physical 1:5 mixture of nicardipine hydrochloride and hydroxypropylmethylcellulose phthalate (HPMCP, HP-55F grade) (nicardipine hydrochloride:HPMCP
- the same as used in Example $ and Comparative Example 4); and the downmost powder X-ray diffraction pattern is the X-ray diffraction pattern of nicardipine hydrochloride bulk substance.
The diffraction angle (2 B ) is plotted on the abscissa and the diffraction intensity (CPS) on the ordinate, . . _ . .y...y Fig. 12 shows the results of a release test with diclofenac sodium-containing solid dispersions prepared in Example 9 and Comparative Example 5. The time (in minutes) is plotted on the abscissa and the release rate (~) of diclofenac sodium is plotted on the ordinate, In the figure, 1 represents the release curve of the solid dispersion obtained in Example 9 and 0 represents the release curve of the solid dispersion obtained in Comparative Example 5.
Fig, 13 shows the results of powder K-ray diffraction analysis of diclofenac sodium-containing solid dispersions. The uppermost powder X-ray diffraction pattern represents the K-ray diffraction pattern of the solid dispersion obtained in Example 9;
the second powder K-ray diffraction pattern as reckoned from the top is the X-ray diffraction pattern of the solid dispersion obtained in Comparative Example 5; the third powder H-ra~~
diffraction pattern as reckoned from the top is the X-ray diffraction pattern of a physical 1:5 mixture of diclofenac sodium and hydroxypropylmethylcellulose phthalate (HPMCP, HP-55F
grade) (diclofenac sodium:HPhICP = the same as used in Example 9 and Comparative Example 5); and the downmost powder X-ray diffraction pattern is the !i-ray diffraction pattern of diclofenac sodium bulk substance. The diffraction angle (2 B ) is plotted on the abscissa and the diffraction intensity (CPS) on the ordinate.
Claims (12)
- Claim 1. A process for producing a solid dispersion of a drug dissolved or dispersed in a polymer carrier which comprises passing a mixture comprising said drug and said polymer through a twin screw compounding extruder having retaining barrels, with said twin screw compounding extruder being equipped with paddle means on each of two screw shafts, whereby said mixture passes between said paddle means and is sheared and compounded thereby, and operating said twin screw extruder while sufficiently heating the barrels to obtain an extrudate in the form of said solid dispersion and wherein said heating is to a temperature below the decomposition temperature of the drug or polymer.
- Claim 2. A process according to Claim 1 wherein said polymer is any natural or synthetic polymer which is capable of being employed as a raw material in the manufacture of pharmaceutical wherein said polymer's functions are not adversely affected by passage through the twin-screw extruder.
- Claim 3. A process according to Claim 2 wherein said polymer is a pH-dependent polymer, a pH-independent polymer or a water-soluble polymer.
- Claim 4. A process according to Claim 3 wherein said process employs a combination of two or more species of said polymer.
- Claim 5. A process according to Claim 1 wherein said polymer has a particle diameter of not greater than 7,000 µm .
- Claim 6. A process according to Claim 1 wherein said polymer has a particle diameter of not greater than 2, 000 µm.
- Claim 7. A process according to Claim 1 wherein said drug is a thermally labile drug and another component of the solid dispersion is an aqueous solution or dispersion of a plasticizer, wherein said plasticizer has the property of lowering the transition temperature of the polymer.
- Claim 8. A process according to Claim 7 wherein said plasticizer is selected from the group consisting essentially of cetanol, medium chain triglycerides, polyoxyethylenepolyoxypropylene glycol, and macrogols (200, 300, 400, 600, 1,000, 1,500, 1,540, 4,000, 6,000, 20,000).
- Claim 9. A process according to Claim 1 wherein said polymer is a thermally labile polymer and another component of the solid dispersion is an aqueous solution or dispersion of a plasticizer, wherein said plasticizer has the property of lowering the transition temperature of the polymer.
- Claim 10. A process according to Claim 9 wherein said plasticizer is selected from the group consisting essentially of cetanol, medium chain triglycerides, polyoxyethylenepolyoxypropylene glycol, and macrogols (200, 300, 400, 600, 1,000, 1,500, 1,540, 4,000, 6,000, 20,000).
- Claim 11. A process according to Claim 1 wherein said drug is a non-heat labile drug, wherein said drug is not decomposed at any temperature not exceeding 50°C.
- Claim 12. A process according to Claim 1 where said drug is selected from the group consisting of antipyretic agents, analgesic agents, antiinflammatory agents, antiulcer agents, coronary vasodilators, peripheral vasodilators, antibiotics, synthetic antimicrobial agents, antispasmodic agents, antitussive and antiasthmatic agents, bronchodilators, diuretics, muscle relaxants, cerebral metabolism improving agents, minor tranquilizers, major tranquilizers, .beta.-blockers, antiarrhythmic agents, antigout agents, anticoagulants, antiepileptics, anthistaminics, antiemetics, antihypertensive agents, sympathomimetic agents, expectorants, oral antidiabetic agents, cardiovascular system drugs, iron preparations, vitamins, therapeutic agents for pollakiuria, and angiotensin-converting enzyme inhibitors.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11255491 | 1991-04-16 | ||
| JPHEI-3/112,554 | 1991-04-16 | ||
| PCT/JP1992/000470 WO1992018106A1 (en) | 1991-04-16 | 1992-04-14 | Method of manufacturing solid dispersion |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2108575A1 CA2108575A1 (en) | 1992-10-17 |
| CA2108575C true CA2108575C (en) | 2002-10-22 |
Family
ID=14589572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002108575A Expired - Lifetime CA2108575C (en) | 1991-04-16 | 1992-04-14 | Method of manufacturing solid dispersion |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US5456923A (en) |
| EP (1) | EP0580860B2 (en) |
| JP (1) | JP2527107B2 (en) |
| KR (1) | KR0182801B1 (en) |
| AT (1) | ATE159426T1 (en) |
| AU (1) | AU1537292A (en) |
| CA (1) | CA2108575C (en) |
| DE (1) | DE69222847T3 (en) |
| DK (1) | DK0580860T4 (en) |
| ES (1) | ES2111065T5 (en) |
| GR (1) | GR3025864T3 (en) |
| WO (1) | WO1992018106A1 (en) |
Families Citing this family (273)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5266331A (en) * | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
| JP3722293B2 (en) | 1991-12-18 | 2005-11-30 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | Novel pharmaceutical solid dispersion |
| US5968551A (en) | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
| US5958459A (en) * | 1991-12-24 | 1999-09-28 | Purdue Pharma L.P. | Opioid formulations having extended controlled released |
| US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
| DE69327877T2 (en) * | 1992-10-14 | 2000-10-05 | Nippon Shinyaku Co Ltd | METHOD FOR SHIFTING A CRYSTAL CONDITION |
| US5811547A (en) * | 1992-10-14 | 1998-09-22 | Nippon Shinyaju Co., Ltd. | Method for inducing crystalline state transition in medicinal substance |
| ATE223704T1 (en) * | 1992-10-16 | 2002-09-15 | Nippon Shinyaku Co Ltd | METHOD FOR PRODUCING WAX MATRICES |
| US20080075781A1 (en) * | 1992-11-25 | 2008-03-27 | Purdue Pharma Lp | Controlled release oxycodone compositions |
| US20070275062A1 (en) * | 1993-06-18 | 2007-11-29 | Benjamin Oshlack | Controlled release oxycodone compositions |
| IL110014A (en) | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
| US7740881B1 (en) | 1993-07-01 | 2010-06-22 | Purdue Pharma Lp | Method of treating humans with opioid formulations having extended controlled release |
| US5879705A (en) * | 1993-07-27 | 1999-03-09 | Euro-Celtique S.A. | Sustained release compositions of morphine and a method of preparing pharmaceutical compositions |
| WO1995005809A1 (en) * | 1993-08-20 | 1995-03-02 | Nippon Shinyaku Co., Ltd. | Gastric remaining preparation, swollen molding, and production process |
| GB2281697A (en) | 1993-09-14 | 1995-03-15 | Euro Celtique Sa | Laxative compositions in capsules |
| US5688510A (en) * | 1993-11-18 | 1997-11-18 | Nippon Shinyaku Co. Ltd. | Process for producing stable medicinal composition, and pharmaceutical preparation |
| DE19509807A1 (en) * | 1995-03-21 | 1996-09-26 | Basf Ag | Process for the preparation of active substance preparations in the form of a solid solution of the active substance in a polymer matrix, and active substance preparations produced using this method |
| GB9422154D0 (en) | 1994-11-03 | 1994-12-21 | Euro Celtique Sa | Pharmaceutical compositions and method of producing the same |
| US20020006438A1 (en) * | 1998-09-25 | 2002-01-17 | Benjamin Oshlack | Sustained release hydromorphone formulations exhibiting bimodal characteristics |
| US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
| ES2210321T3 (en) * | 1994-12-19 | 2004-07-01 | Daiichi Pharmaceutical Co., Ltd. | GRANULAR PREPARATION OF PROLONGED RELEASE AND PRODUCTION PROCEDURE. |
| FR2736550B1 (en) * | 1995-07-14 | 1998-07-24 | Sandoz Sa | PHARMACEUTICAL COMPOSITION IN THE FORM OF A SOLID DISPERSION COMPRISING A MACROLIDE AND A VEHICLE |
| ATE240734T1 (en) * | 1995-07-26 | 2003-06-15 | Kyowa Hakko Kogyo Kk | PREPARATION OF XANTHINDERIVATES AS A SOLID DISPERSION |
| TW487582B (en) | 1995-08-11 | 2002-05-21 | Nissan Chemical Ind Ltd | Method for converting sparingly water-soluble medical substance to amorphous state |
| BR9706897B1 (en) * | 1996-05-20 | 2010-09-21 | pharmaceutical dosage form. | |
| US6139872A (en) * | 1996-08-14 | 2000-10-31 | Henkel Corporation | Method of producing a vitamin product |
| JPH10114682A (en) * | 1996-10-11 | 1998-05-06 | Shimizu Kagaku Kk | Sustained release medicine mixed with clucomannan for internal use |
| US5955475A (en) * | 1997-06-30 | 1999-09-21 | Endo Pharmaceuticals Inc. | Process for manufacturing paroxetine solid dispersions |
| DE69837903T2 (en) | 1997-08-11 | 2008-02-14 | Pfizer Products Inc., Groton | Solid pharmaceutical dispersions with increased bioavailability |
| EP1741424B1 (en) | 1997-08-11 | 2018-10-03 | Pfizer Products Inc. | Solid pharmaceutical dispersions with enhanced bioavailabilty |
| HN1998000115A (en) * | 1997-08-21 | 1999-06-02 | Warner Lambert Co | SOLID PHARMACEUTICAL DOSAGE FORMS |
| US6013280A (en) * | 1997-10-07 | 2000-01-11 | Fuisz Technologies Ltd. | Immediate release dosage forms containing microspheres |
| WO1999034780A1 (en) * | 1998-01-12 | 1999-07-15 | Bühler AG | Method and device for capsulating active ingredients |
| IE980115A1 (en) * | 1998-02-16 | 2000-02-09 | Biovail Internat Ltd | Solubilizing delivery systems and method of manufacture |
| AU759264B2 (en) * | 1998-05-27 | 2003-04-10 | Euro-Celtique S.A. | Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds, to the upper respiratory tract and/or the ear |
| DE19842914A1 (en) * | 1998-09-18 | 2000-03-23 | Basf Ag | Test system to characterize the compatibility of biologically active substances and polyvinylpyrrolidone |
| DE19842753A1 (en) | 1998-09-18 | 2000-03-23 | Bayer Ag | Multiple-unit retard oral dosage formulation having controlled release independent of agitation and food effect, containing particles of combination of drug and hydroxypropyl cellulose |
| US6350786B1 (en) † | 1998-09-22 | 2002-02-26 | Hoffmann-La Roche Inc. | Stable complexes of poorly soluble compounds in ionic polymers |
| US6806294B2 (en) | 1998-10-15 | 2004-10-19 | Euro-Celtique S.A. | Opioid analgesic |
| US6455526B1 (en) | 1998-12-16 | 2002-09-24 | Aventis Pharmaceuticals, Inc. | Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same |
| OA11728A (en) * | 1998-12-16 | 2005-02-01 | Aventis Pharma Inc | Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same. |
| DE60039377D1 (en) | 1999-02-09 | 2008-08-21 | Pfizer Prod Inc | Compositions of basic drugs with improved bioavailability |
| US6706283B1 (en) * | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
| EP1027886B1 (en) | 1999-02-10 | 2008-07-09 | Pfizer Products Inc. | Pharmaceutical solid dispersions |
| JP2000281561A (en) * | 1999-03-26 | 2000-10-10 | Ajinomoto Co Inc | New solid dispersion preparation by solvent method |
| DE19918325A1 (en) | 1999-04-22 | 2000-10-26 | Euro Celtique Sa | Extruded drug dosage form, e.g. granulate for tableting, comprising an active agent in a polysaccharide-containing matrix, giving a release profile which is controllable by extrusion conditions and/or the inclusion of additives |
| US7300667B1 (en) | 1999-05-27 | 2007-11-27 | Euro-Celtique, S.A. | Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds, to the lower respiratory tract |
| US7297344B1 (en) | 1999-05-27 | 2007-11-20 | Euro-Celtique, S.A. | Preparations for the promotion of wound healing in the upper respiratory tract and/or ear |
| ES2274372T3 (en) | 1999-05-27 | 2007-05-16 | Euro-Celtique S.A. | USE OF ANTISEPTICS IN THE MANUFACTURE OF A PHARMACEUTICAL PREPARATION FOR THE PREVENTION OR TREATMENT OF INFLAMMATIONS INSIDE THE HUMAN BODY. |
| DE19945982A1 (en) | 1999-09-24 | 2001-03-29 | Knoll Ag | Velocity-determined particles |
| DE19949897A1 (en) * | 1999-10-15 | 2001-04-19 | Rainer Rogasch | Shaped article, e.g. in stick form, for controlled release of drugs in wounds or body cavities, comprising hydrophilic outer phase, lipophilic inner phase and drug, e.g. antibiotic |
| EP2295043A1 (en) | 1999-10-29 | 2011-03-16 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
| US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
| WO2001034119A2 (en) | 1999-11-12 | 2001-05-17 | Abbott Laboratories | Inhibitors of crystallization in a solid dispersion |
| US7364752B1 (en) | 1999-11-12 | 2008-04-29 | Abbott Laboratories | Solid dispersion pharamaceutical formulations |
| TR200201617T2 (en) | 1999-12-23 | 2002-10-21 | Pfizer Products Inc. | Pharmaceutical compositions that provide enhanced drug concentrations |
| KR20030019326A (en) * | 2000-03-21 | 2003-03-06 | 니뽄 신야쿠 가부시키가이샤 | Sustained release oral preparations |
| DE10026698A1 (en) | 2000-05-30 | 2001-12-06 | Basf Ag | Self-emulsifying active ingredient formulation and use of this formulation |
| DE10031044A1 (en) | 2000-06-26 | 2002-01-03 | Bayer Ag | Endoparasiticidal agents for voluntary oral ingestion by animals |
| JP3563070B2 (en) * | 2000-07-17 | 2004-09-08 | 山之内製薬株式会社 | Oral absorption improving pharmaceutical composition |
| US7115279B2 (en) | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| US20040013736A1 (en) * | 2000-09-25 | 2004-01-22 | Tomio Nakano | Process for producing medicinal solid dispersion |
| CN101317825A (en) | 2000-10-30 | 2008-12-10 | 欧罗赛铁克股份有限公司 | Controlled release hydrocodone formulations |
| ITMI20010141A1 (en) * | 2001-01-26 | 2002-07-26 | Giuliani Spa | PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL OR DIETETIC COMPOSITIONS FOR VEHICULATION IN THE INTESTINE OF LABILE SUBSTANCES |
| GB0104752D0 (en) * | 2001-02-27 | 2001-04-18 | Astrazeneca Ab | Pharmaceutical compositions |
| CA2439366A1 (en) * | 2001-02-27 | 2002-09-06 | Julie Cahill | Pharmaceutical formulation comprising bicalutamide |
| US6465014B1 (en) * | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
| US20110104214A1 (en) | 2004-04-15 | 2011-05-05 | Purdue Pharma L.P. | Once-a-day oxycodone formulations |
| UA81224C2 (en) | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Dosage form of oxycodone and use thereof |
| KR20040011549A (en) * | 2001-06-22 | 2004-02-05 | 화이자 프로덕츠 인크. | Pharmaceutical Compositions Comprising Low-Solubility and/or Acid-Sensitive Drugs and Neutralized Acidic Polymers |
| EP1269994A3 (en) | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
| ES2333645T3 (en) * | 2001-06-22 | 2010-02-25 | Bend Research, Inc. | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF MEDICINES AND NEUTRAL POLYMERS. |
| JP2004534811A (en) * | 2001-06-22 | 2004-11-18 | ファイザー・プロダクツ・インク | Pharmaceutical composition comprising a polymer and drug assembly |
| ES2284871T3 (en) * | 2001-06-22 | 2007-11-16 | Pfizer Products Inc. | PHARMACEUTICAL COMPOSITIONS CONTAINING A SOLID DISPERSION OF LITTLE SOLUBLE PHARMACO AND A SOLUBILITY POTENTIATING POLYMER. |
| DE10141650C1 (en) | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Safe transdermal therapeutic system for administration of fentanyl or analogous analgesics, having matrix layer of carboxy group-free polyacrylate adhesive providing high permeation rate |
| SE0103424D0 (en) * | 2001-10-15 | 2001-10-15 | Astrazeneca Ab | Pharmaceutical formulation |
| US7491407B2 (en) * | 2001-10-31 | 2009-02-17 | North Carolina State University | Fiber-based nano drug delivery systems (NDDS) |
| AR038375A1 (en) * | 2002-02-01 | 2005-01-12 | Pfizer Prod Inc | PHARMACEUTICAL COMPOSITIONS OF INHIBITORS OF THE PROTEIN OF TRANSFER OF ESTERES DE COLESTERILO |
| EP1920766B1 (en) | 2002-02-01 | 2017-08-23 | Bend Research, Inc | Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials |
| KR20040083493A (en) * | 2002-02-01 | 2004-10-02 | 화이자 프로덕츠 인크. | Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor |
| KR100664822B1 (en) | 2002-02-01 | 2007-01-04 | 화이자 프로덕츠 인코포레이티드 | Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
| US20030204180A1 (en) * | 2002-04-30 | 2003-10-30 | Kimberly-Clark Worldwide, Inc. | Temperature responsive delivery systems |
| ES2333318T3 (en) | 2002-08-12 | 2010-02-19 | Bend Research, Inc. | PHARMACEUTICAL COMPOSITIONS OF MEDICINES WITH SEMIORDENATED STRUCTURE AND OF POLYMER. |
| ATE407670T1 (en) | 2002-12-20 | 2008-09-15 | Pfizer Prod Inc | DOSAGE FORM CONTAINING A CETP INHIBITOR AND A HMG-COA REDUCTASE INHIBITOR |
| WO2004069180A2 (en) * | 2003-01-31 | 2004-08-19 | Smithkline Beecham Corporation | Solid dispersion compositions |
| EP1594468A2 (en) * | 2003-02-03 | 2005-11-16 | Novartis AG | Process for preparing a solid dispersion pharmaceutical product |
| US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| JP2007511500A (en) * | 2003-11-14 | 2007-05-10 | ファイザー・プロダクツ・インク | Solid amorphous dispersion of MTP inhibitors for the treatment of obesity |
| WO2005056542A1 (en) * | 2003-12-09 | 2005-06-23 | Pfizer Inc. | Compositions comprising an hiv protease inhibitor |
| JP2007520543A (en) | 2004-02-04 | 2007-07-26 | ファイザー・プロダクツ・インク | Substituted quinoline compounds |
| US20050238721A1 (en) * | 2004-04-07 | 2005-10-27 | Acquarulo Lawrence A Jr | One step compounding extrusion of drug filled polymers |
| EP1750669A1 (en) * | 2004-05-04 | 2007-02-14 | Boehringer Ingelheim International Gmbh | Solid pharmaceutical form comprising an ltb4 antagonist |
| GEP20094723B (en) | 2004-05-25 | 2009-07-10 | Pfizer Prod Inc | Tetraazabenzo [e] azulene derivatives and analogs thereof |
| JP2008501009A (en) * | 2004-05-28 | 2008-01-17 | ファイザー・プロダクツ・インク | Pharmaceutical composition with enhanced performance |
| MY191349A (en) * | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
| US8604055B2 (en) | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
| ES2644450T3 (en) | 2004-12-31 | 2017-11-29 | Dr. Reddy's Laboratories Ltd. | New benzylamine derivatives as CETP inhibitors |
| US8617604B2 (en) | 2005-02-03 | 2013-12-31 | Bend Research, Inc. | Pharmaceutical compositions with enhanced performance |
| EP1690528A1 (en) * | 2005-02-11 | 2006-08-16 | Abbott GmbH & Co. KG | Process for the preparation of dosage forms comprising a solid dispersion of a microcrystalline active agent |
| US20100047338A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
| US20080213339A1 (en) * | 2005-08-02 | 2008-09-04 | Roger Imboden | Pharmaceutical Composition Containing Indometacin and/or Acemetacin |
| EP2664337B1 (en) | 2005-09-27 | 2019-08-14 | TissueTech, Inc. | Amniotic membrane preparations and purified compositions and methods of use |
| US8187639B2 (en) | 2005-09-27 | 2012-05-29 | Tissue Tech, Inc. | Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment |
| US8022054B2 (en) | 2005-11-28 | 2011-09-20 | Marinus Pharmaceuticals | Liquid ganaxolone formulations and methods for the making and use thereof |
| EP1832281A1 (en) | 2006-03-10 | 2007-09-12 | Abbott GmbH & Co. KG | Process for producing a solid dispersion of an active ingredient |
| EP2056818B1 (en) | 2006-08-11 | 2011-05-25 | The Johns Hopkins University | Compositions and methods for neuroprotection |
| HUE028086T2 (en) | 2006-09-22 | 2016-11-28 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| US7638541B2 (en) * | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| US7607596B1 (en) | 2007-03-07 | 2009-10-27 | Exxpharma, LLC | Process for enhancing the solubility of poorly soluble drugs |
| US8703204B2 (en) | 2007-05-03 | 2014-04-22 | Bend Research, Inc. | Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer |
| US8309129B2 (en) | 2007-05-03 | 2012-11-13 | Bend Research, Inc. | Nanoparticles comprising a drug, ethylcellulose, and a bile salt |
| US9545384B2 (en) | 2007-06-04 | 2017-01-17 | Bend Research, Inc. | Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate |
| WO2008149192A2 (en) | 2007-06-04 | 2008-12-11 | Pfizer Products Inc. | Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer |
| MX2010000617A (en) | 2007-07-17 | 2010-05-17 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor. |
| AU2008279447A1 (en) * | 2007-07-19 | 2009-01-29 | Metabolex, Inc. | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders |
| CA2990445C (en) | 2007-08-21 | 2020-05-05 | Board Of Regents, The University Of Texas System | Thermo-kinetic mixing for pharmaceutical applications |
| US8263641B2 (en) | 2007-09-10 | 2012-09-11 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| US20100240711A1 (en) * | 2007-09-21 | 2010-09-23 | Shionogi & Co., Ltd. | Solid preparation comprising npyy5 receptor antagonist |
| EP2601935A1 (en) * | 2007-09-25 | 2013-06-12 | Solubest Ltd. | Compositions comprising lipophilic active compounds and method for their preparation |
| WO2009053635A1 (en) * | 2007-10-11 | 2009-04-30 | L'oreal | Structured cosmetic composition |
| FR2922100B1 (en) * | 2007-10-11 | 2009-12-11 | Oreal | PROCESS FOR THE PREPARATION OF SEMI-SOLID PARTICLES WITH COSMETIC INTEREST |
| US9724362B2 (en) | 2007-12-06 | 2017-08-08 | Bend Research, Inc. | Pharmaceutical compositions comprising nanoparticles and a resuspending material |
| US9233078B2 (en) | 2007-12-06 | 2016-01-12 | Bend Research, Inc. | Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer |
| US20090163561A1 (en) * | 2007-12-21 | 2009-06-25 | Url Pharma, Inc. | Amorphous metaxalone and amorphous dispersions thereof |
| JP5711655B2 (en) * | 2008-03-31 | 2015-05-07 | シマベイ セラピューティクス， インコーポレーテッド | Oxymethylene aryl compounds and uses thereof |
| WO2010027875A2 (en) | 2008-08-27 | 2010-03-11 | Calcimedica Inc. | Compounds that modulate intracellular calcium |
| US20110160222A1 (en) * | 2008-11-26 | 2011-06-30 | Metabolex, Inc. | Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders |
| WO2010067233A1 (en) | 2008-12-08 | 2010-06-17 | Pfizer Inc. | 1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir) |
| CA2761389A1 (en) | 2009-02-05 | 2010-08-12 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
| WO2010114928A2 (en) | 2009-04-03 | 2010-10-07 | F.Hoffmann-La Roche Ag | Compositions and uses thereof |
| EP2421901B1 (en) | 2009-04-24 | 2015-10-28 | Tissue Tech, Inc. | Compositions containing hc ha complex and methods of use thereof |
| RU2012101214A (en) | 2009-06-16 | 2013-07-27 | Пфайзер Инк. | DOSAGE FORMS OF APIKSABAN |
| US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
| CN102666553B (en) | 2009-10-01 | 2015-05-06 | 赛马拜制药公司 | Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts |
| US7718662B1 (en) | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
| NZ629615A (en) | 2009-11-06 | 2016-01-29 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| CN102821754B (en) * | 2010-03-26 | 2014-06-18 | 陶氏环球技术有限责任公司 | Multilayer melt-extruded film |
| US20110236666A1 (en) * | 2010-03-26 | 2011-09-29 | Hall Mark J | Melt-extruded film |
| KR20130080004A (en) * | 2010-03-26 | 2013-07-11 | 다우 글로벌 테크놀로지스 엘엘씨 | Melt-extruded film |
| EP2558866B1 (en) | 2010-04-15 | 2016-08-17 | Tracon Pharmaceuticals, Inc. | Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors |
| WO2011139489A2 (en) | 2010-04-27 | 2011-11-10 | Calcimedica Inc. | Compounds that modulate intracellular calcium |
| JP2013525448A (en) | 2010-04-27 | 2013-06-20 | カルシメディカ，インク． | Compounds that regulate intracellular calcium |
| US20130072519A1 (en) | 2010-05-21 | 2013-03-21 | Edward Lee Conn | 2-phenyl benzoylamides |
| CA2800913C (en) | 2010-06-03 | 2019-07-23 | Pharmacyclics, Inc. | The use of inhibitors of bruton's tyrosine kinase (btk) |
| EP2585048B1 (en) | 2010-06-23 | 2018-04-11 | CymaBay Therapeutics, Inc. | Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| MX2013000201A (en) | 2010-07-02 | 2013-08-21 | Procter & Gamble | Methods of delivering a health care active by administering personal health care articles comprising a filament. |
| AU2011293201B2 (en) | 2010-08-27 | 2015-11-05 | Calcimedica Inc. | Compounds that modulate intracellular calcium |
| JP5941069B2 (en) | 2011-02-07 | 2016-06-29 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | Compounds and methods for kinase regulation and indications therefor |
| RU2013139701A (en) | 2011-02-17 | 2015-03-27 | Ф. Хоффманн-Ля Рош Аг | METHOD FOR CONTROLLED CRYSTALLIZATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT FROM THE STATE OF A COOLED LIQUID BY EXTRUSION OF HOT DECAY |
| AR085279A1 (en) | 2011-02-21 | 2013-09-18 | Plexxikon Inc | SOLID FORMS OF {3- [5- (4-CHLORINE-PHENYL) -1H-PIRROLO [2,3-B] PIRIDINA-3-CARBONIL] -2,4-DIFLUOR-PHENIL} -AMIDE OF PROPANE ACID-1- SULFONIC |
| DE102011015370A1 (en) * | 2011-03-29 | 2012-10-04 | Emodys Gmbh | Preparing a matrix comprises preparing a mixture containing an active agent and a biopolymer e.g. alginate, gum arabic, locust bean gum, karaya gum, tara gum or tragacanth and extruding the obtained mixture |
| WO2012149486A1 (en) | 2011-04-28 | 2012-11-01 | Tissuetech, Inc. | Methods of modulating bone remodeling |
| ES2822301T3 (en) | 2011-06-10 | 2021-04-30 | Tissuetech Inc | Fetal Support Tissue Processing Methods |
| US9199967B2 (en) | 2011-08-18 | 2015-12-01 | Dr. Reddy's Laboratories Ltd. | Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors |
| CN103917231B (en) | 2011-09-13 | 2016-09-28 | 药品循环有限责任公司 | Combination formulations of histone deacetylase inhibitor and bendamustine and application thereof |
| CN103958511A (en) | 2011-09-27 | 2014-07-30 | 雷迪博士实验室有限公司 | 5 - benzylaminomethyl - 6 - aminopyrazolo [3, 4 -b] pyridine derivatives as cholesteryl ester -transfer protein (cetp) inhibitors useful for the treatment of atherosclerosis |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| MY168791A (en) | 2012-01-06 | 2018-12-04 | Abide Therapeutics Inc | Carbamate compounds and of making and using same |
| IN2012DE00674A (en) | 2012-03-07 | 2015-08-21 | Nat Inst Of Pharmaceutical Education And Res Niper | |
| SG11201405477XA (en) | 2012-04-06 | 2014-11-27 | Pfizer | Diacylglycerol acyltransferase 2 inhibitors |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| CN110354132A (en) | 2012-06-04 | 2019-10-22 | 药品循环有限责任公司 | The crystalline form of bruton's tyrosine kinase inhibitor |
| JP2015528001A (en) | 2012-07-11 | 2015-09-24 | ティッシュテック，インク． | Composition comprising HC-HA / PTX3 complex and method of use thereof |
| DK2900674T3 (en) | 2012-09-28 | 2017-07-03 | Univ Washington Through Its Center For Commercialization | RELATIONSHIPS AND PROCEDURES FOR PREVENTION, TREATMENT AND / OR PROTECTION AGAINST SENSITIVE CELL DEATH |
| WO2014059333A1 (en) | 2012-10-12 | 2014-04-17 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| KR102191562B1 (en) * | 2012-11-07 | 2020-12-15 | 에스케이바이오팜 주식회사 | Solid dispersions of insoluble drug and preparation method therof |
| US20170071930A1 (en) | 2012-11-19 | 2017-03-16 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical compositions of cetp inhibitors |
| JP6150518B2 (en) | 2012-12-27 | 2017-06-21 | 花王株式会社 | Method for producing polyphenol composition |
| WO2014128564A2 (en) | 2013-02-21 | 2014-08-28 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical compositions of cetp inhibitors |
| AU2014236135A1 (en) | 2013-03-14 | 2015-09-10 | Thomas Jefferson University | Androgen receptor down-regulating agents and uses thereof |
| EP2837391B1 (en) | 2013-08-12 | 2017-05-10 | Shin-Etsu Chemical Co., Ltd. | Hypromellose acetate succinate for use as hot-melt extrusion carrier, hot-melt extrusion composition, and method for producing hot-melt extrudate |
| US9808472B2 (en) | 2013-08-12 | 2017-11-07 | Tokai Pharmaceuticals, Inc. | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
| US9296882B2 (en) | 2013-09-04 | 2016-03-29 | Zzyzx Polymers LLC | Methods for increasing throughput rates of solid-state extrusion devices |
| WO2015054283A1 (en) | 2013-10-08 | 2015-04-16 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| US20150104508A1 (en) * | 2013-10-12 | 2015-04-16 | Zzyzx Polymers LLC | Devices, compositions, and methods for fabricating drug delivery systems |
| AU2014360446A1 (en) | 2013-12-05 | 2016-06-09 | Pharmacyclics, Llc | Inhibitors of Bruton's tyrosine kinase |
| EP3104853B1 (en) | 2014-02-10 | 2019-10-02 | Respivant Sciences GmbH | Mast cell stabilizers treatment for systemic disorders |
| SI3104854T1 (en) | 2014-02-10 | 2020-09-30 | Respivant Sciences Gmbh | Mast cell stabilizers for lung disease treatment |
| MX2016012008A (en) | 2014-03-17 | 2016-12-07 | Pfizer | Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders. |
| JP6537147B2 (en) * | 2014-03-18 | 2019-07-03 | 武田薬品工業株式会社 | Solid dispersion |
| EP3134418A4 (en) | 2014-04-23 | 2018-01-03 | The Research Foundation for The State University of New York | A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith |
| TW201603818A (en) | 2014-06-03 | 2016-02-01 | 組織科技股份有限公司 | Compositions and methods |
| WO2016031651A1 (en) | 2014-08-29 | 2016-03-03 | 花王株式会社 | Method for producing solid dispersion containing hardly soluble polyphenol |
| US9839644B2 (en) | 2014-09-09 | 2017-12-12 | ARKAY Therapeutics, LLC | Formulations and methods for treatment of metabolic syndrome |
| US20160113906A1 (en) * | 2014-09-19 | 2016-04-28 | Board Of Regents, The University Of Texas System | Methods of preparing extrudates |
| US9359316B1 (en) | 2014-11-25 | 2016-06-07 | Concentric Analgesics, Inc. | Prodrugs of phenolic TRPV1 agonists |
| EP3253766B1 (en) | 2015-02-06 | 2019-09-04 | University of Washington | Compounds and methods for preventing or treating sensory hair cell death |
| US10227333B2 (en) | 2015-02-11 | 2019-03-12 | Curtana Pharmaceuticals, Inc. | Inhibition of OLIG2 activity |
| US20160243288A1 (en) | 2015-02-23 | 2016-08-25 | Tissuetech, Inc. | Apparatuses and methods for treating ophthalmic diseases and disorders |
| CA2977521C (en) | 2015-02-27 | 2024-03-19 | Curtana Pharmaceuticals, Inc. | 1-(aryl)-3-(heteroaryl) urea compounds and their use as olig2 inhibitors |
| AU2016226279B2 (en) | 2015-03-03 | 2021-11-11 | Pharmacyclics Llc | Pharmaceutical formulations of Bruton's tyrosine kinase inhibtor |
| MA41827A (en) | 2015-03-27 | 2018-01-30 | Pharmacyclics Llc | SOLVATED FORMS OF A BRUTON TYROSINE KINASE INHIBITOR |
| MA41828A (en) | 2015-03-27 | 2018-01-30 | Pharmacyclics Llc | CO-CRYSTALS OF A TYROSINE KINASE INHIBITOR FROM BRUTON |
| MX2017014344A (en) | 2015-05-11 | 2018-04-11 | Abide Therapeutics Inc | Methods of treating inflammation or neuropathic pain. |
| CN107847526A (en) | 2015-05-20 | 2018-03-27 | 组织技术公司 | For preventing the propagation of epithelial cell and the composition and method of the conversion of epithelium mesenchyma |
| MX2017015238A (en) | 2015-05-28 | 2018-02-19 | Dr Reddy´S Laboratories Ltd | Oral composition of celecoxib for treatment of pain. |
| US10265296B2 (en) | 2015-08-07 | 2019-04-23 | Respivant Sciences Gmbh | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
| EP3331522A1 (en) | 2015-08-07 | 2018-06-13 | Patara Pharma LLC | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
| AR106018A1 (en) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS |
| EP3340982B1 (en) | 2015-08-26 | 2021-12-15 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of immune and inflammatory disorders |
| US20170209462A1 (en) | 2015-08-31 | 2017-07-27 | Pharmacyclics Llc | Btk inhibitor combinations for treating multiple myeloma |
| JP2019505498A (en) | 2015-12-16 | 2019-02-28 | ザ・ウォルター・アンド・エリザ・ホール・インスティテュート・オブ・メディカル・リサーチ | Inhibition of cytokine-induced SH2 protein in NK cells |
| MA43649A (en) | 2016-01-19 | 2018-11-28 | Janssen Pharmaceutica Nv | FORMULATIONS / COMPOSITIONS INCLUDING A BTK INHIBITOR |
| WO2017125424A1 (en) | 2016-01-19 | 2017-07-27 | Janssen Pharmaceutica Nv | Formulations/compositions comprising a btk inhibitor |
| TW201733600A (en) | 2016-01-29 | 2017-10-01 | 帝聖工業公司 | Fetal support tissue products and methods of use |
| US10851123B2 (en) | 2016-02-23 | 2020-12-01 | Concentric Analgesics, Inc. | Prodrugs of phenolic TRPV1 agonists |
| CN116509869A (en) | 2016-04-04 | 2023-08-01 | 希诺皮亚生物科学公司 | Treatment of extrapyramidal syndrome with trapidil |
| CA3024556A1 (en) | 2016-05-12 | 2017-11-16 | The Regents Of The University Of Michigan | Ash1l inhibitors and methods of treatment therewith |
| BR112018071722B1 (en) | 2016-05-13 | 2024-02-27 | Merck Patent Gmbh | USE OF AMINO SUGAR AS PLASTIFICANT, POWDER COMPOSITION AND ITS PRODUCTION PROCESS |
| WO2017194578A1 (en) | 2016-05-13 | 2017-11-16 | Merck Patent Gmbh | Particle size and distribution of polymer for melt extrusion application |
| JP2019516773A (en) | 2016-05-25 | 2019-06-20 | コンセントリック アナルジジックス，インク． | Prodrugs of phenol TRPV1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia |
| WO2017205762A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
| WO2017205769A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
| WO2017205766A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
| CA3029262A1 (en) | 2016-06-27 | 2018-01-04 | Achillion Pharmaceuticals, Inc. | Quinazoline and indole compounds to treat medical disorders |
| EP3957629B1 (en) | 2016-07-18 | 2023-09-06 | Arthrosi Therapeutics, Inc. | Process for making deuterated hydroxy-benzbromarone and intermediates thereof |
| EP3493807A1 (en) | 2016-08-03 | 2019-06-12 | CymaBay Therapeutics, Inc. | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions |
| AR109179A1 (en) | 2016-08-19 | 2018-11-07 | Pfizer | DIACILGLICEROL ACILTRANSFERASA 2 INHIBITORS |
| JP7028860B2 (en) | 2016-08-26 | 2022-03-02 | カーテナ ファーマシューティカルズ，インク． | Inhibition of OLIG2 activity |
| EP3506893A4 (en) | 2016-08-31 | 2020-01-22 | Respivant Sciences GmbH | Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis |
| WO2018067341A1 (en) | 2016-10-07 | 2018-04-12 | Patara Pharma, LLC | Cromolyn compositions for treatment of pulmonary fibrosis |
| EP3534883A1 (en) | 2016-11-07 | 2019-09-11 | Merck Patent GmbH | Instant release capsule based on hot melt extruded polyvinyl alcohol |
| EP3534882A1 (en) | 2016-11-07 | 2019-09-11 | Merck Patent GmbH | Anti-alcohol-induced dose dumping tablet based on polyvinyl alcohol |
| KR20190082848A (en) | 2016-11-07 | 2019-07-10 | 메르크 파텐트 게엠베하 | Controlled release tablet based on polyvinyl alcohol and its preparation |
| WO2018093950A1 (en) | 2016-11-16 | 2018-05-24 | Abide Therapeutics, Inc. | Pharmaceutical formulations |
| PE20191239A1 (en) | 2016-11-16 | 2019-09-16 | Abide Therapeutics Inc | CRYSTAL FORMS OF A MAGL INHIBITOR |
| CA3056030A1 (en) | 2017-03-10 | 2018-09-13 | Pfizer Inc. | Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors |
| CN109320428A (en) * | 2017-08-01 | 2019-02-12 | 浙江普利药业有限公司 | A kind of Trimebutine Maleate crystal form and preparation method thereof |
| EP3675865A4 (en) | 2017-09-01 | 2021-06-02 | University of Washington | Crystalline forms of compounds for preventing or treating sensory hair cell death |
| EP3706867A4 (en) | 2017-11-07 | 2021-08-11 | The Regents Of The University Of Michigan | Therapeutic combination for treatment of cerebellar ataxia |
| US10632209B2 (en) | 2017-11-10 | 2020-04-28 | The Regents Of The University Of Michigan | ASH1L inhibitors and methods of treatment therewith |
| WO2019113469A1 (en) | 2017-12-07 | 2019-06-13 | The Regents Of The University Of Michigan | Nsd family inhibitors and methods of treatment therewith |
| US11685722B2 (en) | 2018-02-28 | 2023-06-27 | Curtana Pharmaceuticals, Inc. | Inhibition of Olig2 activity |
| EP4155293A1 (en) | 2018-06-07 | 2023-03-29 | The Regents of The University of Michigan | Prc1 inhibitors and methods of treatment therewith |
| EP3830078A4 (en) | 2018-07-27 | 2022-03-30 | Concentric Analgesics, Inc. | Pegylated prodrugs of phenolic trpv1 agonists |
| US20230022157A1 (en) | 2018-08-20 | 2023-01-26 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement factor d medical disorders |
| US20200069742A1 (en) | 2018-08-29 | 2020-03-05 | Myos Rens Technology Inc. | Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals |
| KR102614808B1 (en) | 2018-08-31 | 2023-12-19 | 화이자 인코포레이티드 | Combination for the treatment of NASH/NAFLD and related diseases |
| US20200108102A1 (en) | 2018-10-03 | 2020-04-09 | Myos Rens Technology Inc. | Spray dried follistatin product |
| EP3866773A4 (en) | 2018-10-16 | 2022-10-26 | Georgia State University Research Foundation, Inc. | Carbon monoxide prodrugs for the treatment of medical disorders |
| WO2020096660A1 (en) | 2018-11-06 | 2020-05-14 | Myos Rens Technology, Inc. | Methods and compositions for improving skeletal muscle protein fractional synthetic rate |
| SG11202106304RA (en) | 2018-12-31 | 2021-07-29 | Biomea Fusion Llc | Irreversible inhibitors of menin-mll interaction |
| US11833186B2 (en) | 2019-02-01 | 2023-12-05 | Myos Corp. | Methods and compositions for improving quality of life and increasing activity in aging and chronically ill mammals |
| US20220265630A1 (en) | 2019-03-15 | 2022-08-25 | Unicycive Therapeutics Inc. | Nicorandil derivatives |
| EP3883548A4 (en) * | 2019-04-08 | 2022-11-09 | Cosci Med-tech Co. Ltd. | Methods of improving pharmaceutical substance solubilization and products thereof |
| JP2022529930A (en) | 2019-04-19 | 2022-06-27 | ファイザー・インク | Antiproliferative drug for treating PAH |
| US20220387402A1 (en) | 2019-05-20 | 2022-12-08 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
| CA3144848C (en) | 2019-06-28 | 2023-11-21 | Pfizer Inc. | 5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases |
| TW202115086A (en) | 2019-06-28 | 2021-04-16 | 美商輝瑞大藥廠 | Bckdk inhibitors |
| TWI771766B (en) | 2019-10-04 | 2022-07-21 | 美商輝瑞股份有限公司 | Diacylglycerol acyltransferase 2 inhibitor |
| JP2022058085A (en) | 2020-02-24 | 2022-04-11 | ファイザー・インク | Combination of inhibitors of diacylglycerol acyltransferase 2 and inhibitors of acetyl-coa carboxylase |
| JP2021134211A (en) | 2020-02-24 | 2021-09-13 | ファイザー・インク | Combinations for treating nafld/nash and related diseases |
| CN115427403A (en) | 2020-04-21 | 2022-12-02 | H.隆德贝克有限公司 | Synthesis of monoacylglycerol lipase inhibitors |
| BR112022024527A2 (en) | 2020-06-09 | 2022-12-27 | Pfizer | SPYRO COMPOUNDS AS MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF |
| JP2023533982A (en) | 2020-07-10 | 2023-08-07 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | GAS41 inhibitor and method of use thereof |
| WO2022133064A1 (en) | 2020-12-16 | 2022-06-23 | Biomea Fusion, Inc. | Fused pyrimidine compounds as inhibitors of menin-mll interaction |
| WO2022150525A1 (en) | 2021-01-06 | 2022-07-14 | Awakn Life Sciences | Mdma in the treatment of alcohol use disorder |
| EP4337316A1 (en) | 2021-05-11 | 2024-03-20 | Awakn Ls Europe Holdings Limited | Therapeutic aminoindane compounds and compositions |
| EP4346788A2 (en) | 2021-06-03 | 2024-04-10 | Arcadia Medicine, Inc. | Enantiomeric entactogen compositions and methods of their use |
| CA3228627A1 (en) | 2021-08-11 | 2023-02-16 | Thomas Butler | Covalent inhibitors of menin-mll interaction for diabetes mellitus |
| WO2023022912A1 (en) | 2021-08-20 | 2023-02-23 | Biomea Fusion, Inc. | Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer |
| WO2023027966A1 (en) | 2021-08-24 | 2023-03-02 | Biomea Fusion, Inc. | Pyrazine compounds as irreversible inhibitors of flt3 |
| WO2023039240A1 (en) | 2021-09-13 | 2023-03-16 | Biomea Fusion, Inc. | IRREVERSIBLE INHIBITORS OF KRas |
| WO2023086341A1 (en) | 2021-11-09 | 2023-05-19 | Biomea Fusion, Inc. | Inhibitors of kras |
| TW202337429A (en) | 2021-12-01 | 2023-10-01 | 美商輝瑞股份有限公司 | Bckdk inhibitors and/or degraders |
| WO2023105387A1 (en) | 2021-12-06 | 2023-06-15 | Pfizer Inc. | Melanocortin 4 receptor antagonists and uses thereof |
| TW202340177A (en) | 2021-12-30 | 2023-10-16 | 美商拜歐米富士恩股份有限公司 | Pyrazine compounds as inhibitors of flt3 |
| WO2023139163A1 (en) | 2022-01-19 | 2023-07-27 | Awakn Ls Europe Holdings Limited | 1,3-benzodioxole esters and their therapeutic use |
| WO2023156565A1 (en) | 2022-02-16 | 2023-08-24 | Awakn Ls Europe Holdings Limited | Bridged ring compounds and their therapeutic use as cns agents |
| WO2023235618A1 (en) | 2022-06-03 | 2023-12-07 | Biomea Fusion, Inc. | Fused pyrimidine compounds as inhibitors of menin |
| US20240010649A1 (en) | 2022-07-06 | 2024-01-11 | Oppilan Pharma Limited | Crystalline forms of an s1p receptor modulator |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5257315A (en) * | 1975-11-04 | 1977-05-11 | Sandoz Ag | Tablet for medical preparation |
| DE2549740A1 (en) * | 1975-11-17 | 1977-05-18 | Sandoz Ag | NEW GALENIC FORMS AND METHODS FOR THEIR PRODUCTION |
| US4230687A (en) * | 1978-05-30 | 1980-10-28 | Griffith Laboratories U.S.A., Inc. | Encapsulation of active agents as microdispersions in homogeneous natural polymeric matrices |
| JPS5785316A (en) * | 1980-11-14 | 1982-05-28 | Kanebo Ltd | Preparation of easily absorbable nifedipine preparation |
| JPS58109411A (en) * | 1981-12-23 | 1983-06-29 | Shionogi & Co Ltd | Nifedipine composition for solid preparation |
| JPS6240277A (en) * | 1985-08-15 | 1987-02-21 | Ajinomoto Co Inc | Production of granular food |
| US4778676A (en) * | 1985-12-20 | 1988-10-18 | Warner-Lambert Company | Confectionery delivery system for actives |
| DE3612212A1 (en) * | 1986-04-11 | 1987-10-15 | Basf Ag | METHOD FOR PRODUCING SOLID PHARMACEUTICAL FORMS |
| DE3612211A1 (en) * | 1986-04-11 | 1987-10-15 | Basf Ag | CONTINUOUS TABLET METHOD |
| US4760094A (en) * | 1986-10-21 | 1988-07-26 | American Home Products Corporation (Del.) | Spray dried acetaminophen |
| US4842761A (en) * | 1988-03-23 | 1989-06-27 | International Flavors & Fragrances, Inc. | Compositions and methods for controlled release of fragrance-bearing substances |
| DE3812567A1 (en) * | 1988-04-15 | 1989-10-26 | Basf Ag | METHOD FOR PRODUCING PHARMACEUTICAL MIXTURES |
| DE3827061C1 (en) * | 1988-08-10 | 1990-02-15 | Deutsche Gelatine-Fabriken Stoess & Co Gmbh, 6930 Eberbach, De | |
| DE3830353A1 (en) * | 1988-09-07 | 1990-03-15 | Basf Ag | METHOD FOR THE CONTINUOUS PRODUCTION OF SOLID PHARMACEUTICAL FORMS |
| AU645003B2 (en) * | 1988-11-08 | 1994-01-06 | Takeda Chemical Industries Ltd. | Sustained release preparations |
| JP2893191B2 (en) * | 1988-11-08 | 1999-05-17 | 武田薬品工業株式会社 | Controlled release matrix agent |
| IL92343A0 (en) * | 1988-12-20 | 1990-07-26 | Gist Brocades Nv | Granulate for multiparticulate controlled release oral compositions,their preparation and oral pharmaceutical compositions containing them |
| US5102668A (en) * | 1990-10-05 | 1992-04-07 | Kingaform Technology, Inc. | Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH |
| FR2670398B1 (en) * | 1990-12-14 | 1995-02-17 | Roquette Freres | DIRECTLY COMPRESSIBLE POWDER COMPOSITION AND PROCESS FOR OBTAINING SAME. |
| JP3722293B2 (en) * | 1991-12-18 | 2005-11-30 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | Novel pharmaceutical solid dispersion |
| ATE223704T1 (en) * | 1992-10-16 | 2002-09-15 | Nippon Shinyaku Co Ltd | METHOD FOR PRODUCING WAX MATRICES |
| DE19509807A1 (en) * | 1995-03-21 | 1996-09-26 | Basf Ag | Process for the preparation of active substance preparations in the form of a solid solution of the active substance in a polymer matrix, and active substance preparations produced using this method |
| WO1996009115A1 (en) * | 1994-09-21 | 1996-03-28 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Adsorbent for interleukins, method of removal thereof by adsorption, and device for adsorption |
| HN1998000115A (en) * | 1997-08-21 | 1999-06-02 | Warner Lambert Co | SOLID PHARMACEUTICAL DOSAGE FORMS |
| US5954175A (en) * | 1997-09-02 | 1999-09-21 | Northrop Grumman Corporation | Modularized parallel drivetrain |
| EP0966269A1 (en) * | 1997-10-07 | 1999-12-29 | Fuiz Technologies Ltd. | Immediate release drug delivery forms |
| US6029764A (en) * | 1997-11-12 | 2000-02-29 | Case Corporation | Coordinated control of an active suspension system for a work vehicle |
| DE60039377D1 (en) * | 1999-02-09 | 2008-08-21 | Pfizer Prod Inc | Compositions of basic drugs with improved bioavailability |
| ATE433318T1 (en) * | 1999-02-10 | 2009-06-15 | Pfizer Prod Inc | OSMOTIC SYSTEM FOR ADMINISTRATION OF ACTIVE INGREDIENTS CONTAINING SOLID AMORPHOUS DISPERSIONS |
| EP1027886B1 (en) * | 1999-02-10 | 2008-07-09 | Pfizer Products Inc. | Pharmaceutical solid dispersions |
-
1992
- 1992-04-14 CA CA002108575A patent/CA2108575C/en not_active Expired - Lifetime
- 1992-04-14 JP JP4507772A patent/JP2527107B2/en not_active Expired - Lifetime
- 1992-04-14 EP EP92907654A patent/EP0580860B2/en not_active Expired - Lifetime
- 1992-04-14 WO PCT/JP1992/000470 patent/WO1992018106A1/en active IP Right Grant
- 1992-04-14 KR KR1019930703143A patent/KR0182801B1/en not_active IP Right Cessation
- 1992-04-14 AT AT92907654T patent/ATE159426T1/en active
- 1992-04-14 AU AU15372/92A patent/AU1537292A/en not_active Abandoned
- 1992-04-14 ES ES92907654T patent/ES2111065T5/en not_active Expired - Lifetime
- 1992-04-14 DK DK92907654T patent/DK0580860T4/en active
- 1992-04-14 DE DE69222847T patent/DE69222847T3/en not_active Expired - Lifetime
-
1993
- 1993-12-23 US US08/129,133 patent/US5456923A/en not_active Expired - Lifetime
-
1998
- 1998-01-08 GR GR980400035T patent/GR3025864T3/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69222847T3 (en) | 2005-09-15 |
| ES2111065T3 (en) | 1998-03-01 |
| DK0580860T3 (en) | 1998-05-25 |
| US5456923A (en) | 1995-10-10 |
| DE69222847D1 (en) | 1997-11-27 |
| JP2527107B2 (en) | 1996-08-21 |
| EP0580860B1 (en) | 1997-10-22 |
| CA2108575A1 (en) | 1992-10-17 |
| EP0580860A4 (en) | 1994-06-15 |
| WO1992018106A1 (en) | 1992-10-29 |
| KR0182801B1 (en) | 1999-05-01 |
| GR3025864T3 (en) | 1998-04-30 |
| EP0580860B2 (en) | 2004-12-15 |
| DK0580860T4 (en) | 2005-03-21 |
| AU1537292A (en) | 1992-11-17 |
| EP0580860A1 (en) | 1994-02-02 |
| ATE159426T1 (en) | 1997-11-15 |
| DE69222847T2 (en) | 1998-05-20 |
| ES2111065T5 (en) | 2005-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2108575C (en) | Method of manufacturing solid dispersion | |
| EP0665010B1 (en) | Method of manufacturing wax matrices | |
| US6692769B1 (en) | Sustained-release particles | |
| US5837285A (en) | Fast soluble tablet | |
| US5498422A (en) | Sustained release capsule | |
| EP0717988B1 (en) | Gastric remaining preparation, swollen molding, and production process | |
| FI94923C (en) | Method of preparing a liquid dosage form for oral administration of a pharmaceutically active substance | |
| CA2169376C (en) | Procedure for encapsulating nsaids | |
| EP1595533B1 (en) | Tablet quickly melting in oral cavity | |
| EP0729748A1 (en) | Process for producing stable medicinal composition, and pharmaceutical preparation | |
| HU188234B (en) | Method for producing solid shaped product | |
| EP0076515B1 (en) | Rapidly releasable microcapsules and method for the preparation thereof | |
| JP2000128774A (en) | Production of globular, fine grain including medicine | |
| JPWO2003077827A1 (en) | Method for producing pharmaceutical solid dispersion | |
| EP1323416B1 (en) | Process for producing medicinal solid dispersion | |
| Vidmar et al. | Poly (lactic acid) microencapsulated oxytetracycline: in vitro and in vivo evaluation | |
| JP2000198747A (en) | Sustained-release particle | |
| JPWO2002069932A1 (en) | Foamable composition | |
| JP4806885B2 (en) | Solid dispersions and drugs | |
| JP2527107C (en) | ||
| JP2004024686A (en) | Manufacturing method for pharmaceutical wax matrix |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry | ||
| MKEX | Expiry |
Effective date: 20120414 |